CG Moneta Insights

The Right Test for the Right Clinical Question: Rethinking the Economics of Respiratory Diagnostics

Mon, 14 Sep 2026 19:41:06 GMT

How CLIA-waived host-response testing may help hospitals optimize molecular testing, support antibiotic stewardship, and reduce unnecessary diagnostic expense

Respiratory molecular testing has transformed clinical medicine.

Modern PCR platforms can rapidly identify specific respiratory pathogens with remarkable analytical sensitivity, providing information that can materially affect treatment, infection prevention, isolation, and other clinical decisions.

For many patients, that information is important. For some, it is essential.

But diagnostic stewardship requires healthcare organizations to ask a different question:

What information does the clinician actually need to manage this patient?

If identifying a specific pathogen is expected to change management, molecular testing may be exactly the right diagnostic tool.

But when the primary clinical uncertainty is whether an acute respiratory infection is bacterial or non-bacterial—and whether antibacterial therapy may be appropriate—identifying a broad array of individual pathogens may not always be necessary.

That distinction creates an important opportunity for hospitals.

The objective is not to replace PCR with a less expensive test.

It is to match the diagnostic strategy to the clinical question—and reserve increasingly sophisticated diagnostics for the patients in whom the additional information is expected to create clinical value.

With FebriDx now FDA 510(k)-cleared and CLIA-waived, healthcare organizations have another diagnostic option to consider within that strategy.

The Clinical Question Comes First

FebriDx and molecular PCR testing should not be viewed as interchangeable diagnostics.

They provide different information.

PCR is pathogen-directed. Depending on the assay, molecular testing can detect nucleic acid from specific respiratory viruses and bacteria and help clinicians determine which pathogen may be present.

FebriDx does not identify a specific organism.

Instead, FebriDx measures two host-response biomarkers—myxovirus resistance protein A, or MxA, and C-reactive protein, or CRP—to aid in differentiating bacterial acute respiratory infection from non-bacterial etiology.

FebriDx is an FDA 510(k)-cleared, CLIA-waived, instrument-free point-of-care assay using fingerstick blood, with a result available after approximately 10 minutes.

The distinction can be summarized simply:

PCR asks: What pathogen can we detect?

FebriDx asks: What does the host response suggest about bacterial versus non-bacterial etiology?

Neither question is inherently more important.

The appropriate question depends on the patient.

That is the foundation of diagnostic stewardship.

More Information Does Not Automatically Mean More Clinical Value

Healthcare understandably tends to associate more diagnostic information with better care.

But the amount of information generated by a test and the clinical value of that information are not the same thing.

A highly accurate test can still represent low-value utilization when its result is unlikely to change management.

Conversely, an expensive molecular test can represent extremely high-value care when identifying a pathogen materially affects treatment or another important clinical decision.

The relevant question is therefore not simply:

How much information does this test provide?

It is:

Will this information change what we do for this patient?

This distinction becomes particularly important with broad molecular respiratory panels.

If identifying the pathogen will influence antiviral treatment, infection-control measures, additional diagnostic evaluation, or another important aspect of care, the additional information may fully justify molecular testing.

But if the immediate decision is primarily whether the clinical picture supports bacterial infection and whether antibacterial therapy is appropriate, a different diagnostic approach may sometimes provide information more closely aligned with that question.

That is where host-response testing becomes relevant.

Hospitals Are Already Finding Savings Through Molecular-Test Stewardship

The opportunity to optimize respiratory molecular testing is not theoretical.

Recent health-system studies have demonstrated that more selective molecular-testing strategies can materially reduce utilization and laboratory expense.

A 2026 study in Microbiology Spectrum evaluated an integrated safety-net health system that transitioned from widespread use of a multiplex respiratory pathogen PCR panel to selective use.

During two years of unrestricted testing, the system performed 8,923 respiratory pathogen panels. During the first year of selective use, it performed 184.

Median weekly testing declined from 83 panels to three, and annualized laboratory costs associated with the panel declined from approximately $741,000 to approximately $31,000. The percentage of panels with at least one detected target did not significantly change.

Another 2026 health-system initiative used clinical decision support to encourage smaller respiratory panels when clinically appropriate and reported approximately $2.26 million in reagent savings.

A separate diagnostic-stewardship initiative targeting multiplex pneumonia PCR panels reported a 34% reduction in testing. Using the study's estimated $200 cost per panel, investigators calculated savings of at least $208,000.

These findings are important—but so is what they do not establish.

These studies demonstrate the economic potential of respiratory diagnostic stewardship. They do not establish that substituting FebriDx for molecular testing would produce comparable savings.

That question must be evaluated prospectively within each health system's patient population, clinical pathways, utilization patterns, and cost structure.

Published savings figures should also not be treated as transferable unit economics. The financial opportunity for an individual organization depends on its actual reagent costs, laboratory structure, reimbursement, payer mix, test volume, contractual arrangements, and the extent to which reduced utilization translates into genuinely avoidable expense.

The lesson is therefore not that PCR is too expensive.

It is that inappropriate or unnecessarily broad diagnostic utilization can be expensive.

Where FebriDx May Fit

FebriDx approaches respiratory diagnostic uncertainty differently from molecular testing.

Rather than identifying pathogen genetic material, it evaluates the host response through MxA and CRP.

The assay therefore does not tell the clinician that a patient has influenza, RSV, SARS-CoV-2, or another specific pathogen.

It provides information intended to aid differentiation between bacterial acute respiratory infection and non-bacterial etiology.

The manufacturer's materials appropriately describe FebriDx as complementary to existing diagnostic pathways rather than as a replacement for pathogen testing.

That distinction suggests a potential diagnostic framework:

Clinical assessment → define the clinical question → select the diagnostic approach most appropriate to that question → escalate or add testing when additional information is expected to change management

Within that framework, an appropriately selected patient whose primary clinical uncertainty is bacterial versus non-bacterial etiology may be a candidate for host-response testing.

A patient for whom pathogen identification will influence management may require targeted or multiplex molecular testing.

Other patients may appropriately require both forms of information—or additional diagnostic evaluation.

This is not a proposed clinical protocol.

It is a framework that hospitals can evaluate through infectious disease, laboratory medicine, emergency medicine, ambulatory care, and antimicrobial stewardship leadership.

When Molecular Testing Is the Right Choice

A credible diagnostic-stewardship strategy should never begin with the objective of reducing PCR simply because PCR costs more.

It should begin with the objective of using molecular testing appropriately.

There are many situations in which pathogen identification can be clinically important.

Depending on the patient and clinical circumstances, molecular testing may affect antiviral therapy, infection-prevention or isolation decisions, evaluation of severe respiratory illness, management of immunocompromised patients, public-health considerations, additional diagnostic evaluation, or other treatment decisions.

In those circumstances, the information generated by molecular testing may justify its cost many times over.

This is why diagnostic stewardship should not be confused with diagnostic restriction.

The objective is not to deny clinicians useful information.

It is to ensure that the information being purchased is likely to contribute meaningfully to care.

Molecular sensitivity and clinical specificity are also not synonymous. Highly sensitive molecular testing can sometimes detect nucleic acid whose clinical significance still requires interpretation. That is not a weakness unique to PCR; it is another reason sophisticated diagnostics must always be interpreted within the patient's clinical context.

The Better Economic Metric May Be Cost per Clinically Useful Decision

Comparing the acquisition price of FebriDx with the price of a PCR panel would provide an incomplete—and potentially misleading—economic analysis.

The relevant economic unit may not be cost per test .

It may be cost per clinically useful decision .

Consider two hypothetical examples.

A relatively inexpensive test that fails to answer the clinical question and leads to additional laboratory testing, imaging, delayed treatment, or another encounter may ultimately create more cost.

Conversely, an expensive molecular panel that identifies a pathogen and immediately changes treatment may represent excellent value.

The financial question is therefore not:

Which test costs less?

It is:

What diagnostic pathway provides the information necessary to make an appropriate clinical decision at the lowest total cost without compromising patient care?

That requires looking beyond the test itself.

A meaningful analysis should consider:

direct test and reagent expense,
laboratory labor and processing,
analyzer and capital-equipment requirements,
service and maintenance,
specimen collection and transportation,
turnaround time,
downstream diagnostic utilization,
antibiotic utilization,
reimbursement and payer mix,
patient throughput,
repeat encounters,
and whether the diagnostic result actually changes management.

FebriDx has a materially different operational profile from molecular testing.

It is self-contained and instrument-free. Supporting materials describe less than one minute of hands-on time, with no analyzer or routine instrument calibration or maintenance.

The assay uses fingerstick blood and provides a result after approximately 10 minutes.

Those characteristics do not establish that FebriDx is economically superior to PCR.

They do mean that it belongs in a different economic model.

CLIA-Waived Status Changes the Implementation Equation

The CLIA waiver makes that operational distinction more significant.

FebriDx can be performed in appropriately authorized waived-testing settings without requiring moderate- or high-complexity laboratory certification for the assay.

That potentially allows host-response testing to be deployed closer to where many respiratory treatment decisions occur.

For a health system with multiple emergency departments, urgent care centers, primary care practices, ambulatory clinics, or other eligible point-of-care environments, scalability matters.

A diagnostic strategy requiring an analyzer, capital investment, specialized laboratory infrastructure, and more complex operational requirements can have very different system-wide economics from an instrument-free point-of-care assay.

But CLIA-waived does not mean oversight-free.

Waived sites remain responsible for appropriate certification, staff training, quality-control procedures, documentation, oversight, adherence to the FDA-cleared Instructions for Use, and other applicable requirements. FebriDx implementation materials specifically address external controls, operator procedures, quality documentation, and related responsibilities.

The advantage is therefore not the absence of a quality system.

It is a different level of diagnostic infrastructure.

Scale Can Turn Utilization Into a Strategic Financial Issue

The economics become more significant when viewed across an entire health system.

A hospital network may evaluate thousands or tens of thousands of patients with acute respiratory symptoms each year across emergency departments, urgent care centers, primary care offices, and ambulatory locations.

Small changes in diagnostic utilization can therefore compound rapidly.

But volume alone does not establish a savings opportunity.

Leadership first needs to understand its current state:

How many respiratory molecular tests are being performed?

Which panels are being ordered?

In what patient populations?

What is the actual marginal cost?

How frequently does the result change management?

How often could a more targeted diagnostic strategy have appropriately answered the clinical question?

And what happens downstream when testing is reduced or changed?

Those questions turn a theoretical savings discussion into an actionable diagnostic-stewardship analysis.

Test the Hypothesis Rather Than Assume the Savings

The strongest way to determine whether FebriDx can contribute to a more efficient respiratory diagnostic pathway is to measure it prospectively.

A health system could identify selected emergency department, urgent care, or ambulatory populations in which bacterial versus non-bacterial uncertainty frequently influences treatment decisions.

Before implementation, leadership could establish baseline measures such as:

respiratory molecular tests per 1,000 eligible encounters,
broad versus targeted panel utilization,
diagnostic expense per eligible respiratory encounter,
antibiotic prescribing,
turnaround time,
repeat visits,
escalation of care,
hospital admissions,
provider-level variation,
and other patient-safety outcomes.

FebriDx could then be incorporated into a defined clinical pathway for appropriately selected patients, with molecular testing preserved whenever pathogen identification is clinically important.

The organization could then determine what actually changes.

Success should not be defined by the number of FebriDx tests performed.

It should not even be defined solely by a reduction in PCR utilization.

The relevant questions are broader:

Did unnecessary molecular testing decline?

Was clinically appropriate molecular testing preserved?

Did total diagnostic expense per eligible encounter change?

Did antibiotic decision-making improve?

Were patient-safety outcomes maintained?

Did downstream diagnostic utilization change?

Was the result available early enough to influence treatment?

Did clinicians accept and follow the pathway?

And, ultimately:

Did the organization create more clinical value for each diagnostic dollar spent?

The CMO and CFO Should Be Asking the Same Question

Diagnostic stewardship is one of those areas where clinical and financial stewardship should naturally align.

The CMO might ask:

Are we ordering the most clinically appropriate diagnostic test for this patient?

The CFO might ask:

Are we paying for diagnostic information that materially contributes to care?

Those are not competing priorities.

They are two perspectives on the same resource-allocation decision.

The correct sequence matters.

Clinical appropriateness should determine utilization. Utilization then determines economics.

Cost reduction should not dictate the clinical pathway.

But when a clinically appropriate pathway also avoids testing that does not add sufficient value, better care and better resource stewardship can coexist.

That is a much more sustainable approach to healthcare cost reduction than simply negotiating a lower price per test.

From Lower-Cost Testing to Higher-Value Diagnosis

The future of respiratory diagnostics should not become a contest between PCR and host-response testing.

Hospitals need access to sophisticated molecular diagnostics.

They also need disciplined utilization.

For some patients, clinical assessment may be sufficient.

For others, targeted pathogen testing may be appropriate.

For selected patients in whom bacterial versus non-bacterial uncertainty is influencing treatment, host-response testing may provide useful additional information.

And for patients in whom pathogen identification materially affects management, molecular testing may be exactly the right choice.

The opportunity created by FebriDx's CLIA-waived status is therefore larger than a simple test-price comparison.

It gives healthcare organizations another diagnostic option that can potentially be incorporated into a more targeted, clinically driven respiratory pathway.

Could that pathway reduce unnecessary molecular testing?

Could it lower total diagnostic expense?

Could it support more appropriate antibiotic use?

Could it preserve sophisticated molecular testing for the patients who benefit from the information it provides?

Those questions should be answered with prospective clinical and financial data rather than assumptions.

Because diagnostic stewardship is not about performing fewer tests simply to save money.

It is about ensuring that each test provides enough clinical value to justify the resources required to perform it.

The objective should not be cheaper testing .

It should be higher-value diagnosis .

About FebriDx

FebriDx is an FDA 510(k)-cleared, CLIA-waived, prescription-use point-of-care assay that measures the host-response biomarkers MxA and CRP from fingerstick blood to aid in differentiating bacterial acute respiratory infection from non-bacterial etiology.

Current product materials specify use in patients ages 12 through 64 presenting with symptoms of acute respiratory infection for less than seven days and within three days of fever onset.

FebriDx does not identify specific pathogens and should not be considered a replacement for pathogen-directed testing when organism identification is clinically necessary.

About CG Moneta Consulting

CG Moneta Consulting (CGM) is a vendor-agnostic healthcare consulting and advisory firm that helps healthcare organizations evaluate financial, operational, technology, and clinical opportunities.

CGM works with provider organizations to determine where emerging solutions can create measurable value and whether they align with an organization's clinical, operational, and financial priorities.

Through its strategic relationships, CGM also supports healthcare organizations evaluating FebriDx and its potential role within point-of-care respiratory diagnostics and antimicrobial stewardship initiatives.

Clinical and Regulatory Note

FebriDx does not diagnose specific pathogens, eliminate the need for other testing, or establish that molecular testing is unnecessary in an individual patient. CLIA-waived sites remain responsible for applicable certification, training, quality control, documentation, oversight, and compliance requirements.

Selected References

Jenkins TC, Young HL, Wyles DL, et al. Effects of a diagnostic stewardship intervention to de-implement widespread use of a rapid respiratory multiplex PCR test. Microbiology Spectrum. 2026.

DiLorenzo M, Marsh K, Wang G, et al. Diagnostic stewardship of a multiplex pneumonia PCR panel leads to cost savings and more appropriate patient care. Antimicrobial Stewardship & Healthcare Epidemiology. 2026.

Lucar J, Yee R. Diagnostic Stewardship for Multiplex Respiratory Testing: What We Know and What Needs to Be Done. Clinical Laboratory Medicine. 2024;44(1):45–61.

Shapiro NI, Filbin MR, Hou PC, et al. Diagnostic Accuracy of a Bacterial and Viral Biomarker Point-of-Care Test in the Outpatient Setting. JAMA Network Open. 2022;5(10):e2234588.

FebriDx and the Next Frontier of Outpatient Antibiotic Stewardship

Mon, 14 Sep 2026 16:44:48 GMT

How CLIA-waived host-response testing can bring objective bacterial vs. non-bacterial insight closer to the point of prescribing

For decades, one of the most persistent challenges in outpatient medicine has also been one of the most familiar: a patient presents with an acute respiratory illness, symptoms overlap across etiologies, the clinical examination does not clearly establish whether the process is bacterial or non-bacterial, and a treatment decision must be made before definitive information is available.

Does the patient need an antibiotic?

Or is the more appropriate course to withhold one?

The problem is not a lack of clinical expertise. It is that acute respiratory infections frequently present with nonspecific symptoms, while many commonly used respiratory diagnostics answer a different question: which pathogen is present?

That distinction matters.

Antimicrobial stewardship programs have spent years developing prescribing guidelines, clinician education, EHR interventions, audit-and-feedback programs, and other strategies intended to reduce unnecessary antibiotic exposure.

Yet the prescribing decision still occurs one patient at a time, often while the clinician is managing meaningful diagnostic uncertainty.

FebriDx introduces another source of information into that decision.

Rather than identifying a specific pathogen, FebriDx measures two host-response biomarkers—myxovirus resistance protein A, or MxA, and C-reactive protein, or CRP—to aid in differentiating bacterial acute respiratory infection from non-bacterial etiology.

The recent CLIA waiver materially changes where that information can potentially be obtained.

FebriDx is FDA 510(k)-cleared and CLIA-waived, allowing the assay to be performed in appropriately authorized waived-testing settings rather than requiring moderate- or high-complexity laboratory certification for this test.

For chief medical officers, antimicrobial stewardship committees, infectious disease leaders, ambulatory medical directors, and laboratory leadership, that regulatory development represents more than a change in laboratory classification.

It creates an opportunity to move objective host-response information much closer to the moment an antibiotic is prescribed—or intentionally not prescribed.

The Diagnostic Gap Behind a Stewardship Problem

Antibiotic stewardship is often discussed as a prescribing problem.

At the point of care, however, it is frequently a diagnostic uncertainty problem first.

A patient with cough, fever, congestion, sore throat, malaise, or other respiratory symptoms may have a presentation compatible with multiple etiologies.

Clinical judgment remains central. But in an ambiguous case, the clinician may still have to decide whether antibacterial therapy is warranted without a definitive answer.

That uncertainty can contribute to empiric or defensive antibiotic prescribing.

This is why stewardship cannot be reduced simply to asking clinicians to prescribe fewer antibiotics.

A more clinically useful question is:

What information can we provide clinicians before they have to make the prescribing decision?

Rapid host-response testing is one potential answer.

What FebriDx Actually Measures

FebriDx is a qualitative, visually interpreted, point-of-care immunoassay performed from a fingerstick blood sample.

It measures two host-response biomarkers:

MxA — Myxovirus Resistance Protein A

MxA is an interferon-inducible protein associated with the antiviral host response. The clinical relevance is not that FebriDx identifies which virus is present, but that MxA provides information about the patient's immune response consistent with viral infection.

CRP — C-Reactive Protein

CRP is an acute-phase protein that increases in response to inflammation, including infection. CRP alone is not specific enough to reliably distinguish bacterial from non-bacterial infection.

The clinical concept behind FebriDx is therefore not based on either biomarker in isolation.

It is the combination of the two host-response signals that provides information intended to help differentiate bacterial acute respiratory infection from non-bacterial etiology. The manufacturer's clinical materials describe this dual-biomarker approach as combining viral host-response information from MxA with inflammatory information from CRP.

FebriDx is instrument-free, self-contained, uses capillary blood obtained by fingerstick, and produces a result after approximately 10 minutes.

The current product materials identify the intended population as patients ages 12 through 64 presenting with acute respiratory infection symptoms for less than seven days and within three days of fever onset.

Those intended-use parameters matter.

CLIA-waived status does not turn FebriDx into a universal respiratory diagnostic. The assay should be used according to its FDA-cleared labeling and Instructions for Use.

Host Response and Pathogen Detection Answer Different Clinical Questions

FebriDx should not be viewed as a replacement for influenza, SARS-CoV-2, RSV, multiplex molecular panels, cultures, or other pathogen-specific diagnostics.

Those tests and FebriDx provide different kinds of information.

Pathogen-directed testing asks:

What organism can be detected?

Host-response testing asks:

What does the patient's immune response suggest about bacterial versus non-bacterial etiology?

That distinction can matter when the central treatment question is not simply whether a particular virus or bacterium is present, but whether antibacterial therapy is warranted.

The manufacturer's own positioning appropriately describes FebriDx as complementary to existing diagnostic pathways. It is not intended to replace clinical judgment, pathogen testing, or clinical guidelines.

For stewardship leaders, that is the most appropriate framework.

FebriDx is not simply another respiratory pathogen test.

It may occupy a different position in the diagnostic pathway.

Why Negative Predictive Value Matters

A central clinical attribute of FebriDx is its performance in supporting rule-out of bacterial infection within its evaluated patient population.

The manufacturer reports a negative predictive value of approximately 99% for ruling out bacterial infection, based on the supporting clinical study population.

That number requires appropriate interpretation.

Negative predictive value is prevalence-dependent.

A 99% NPV should not be interpreted as meaning FebriDx is "99% accurate," nor should a negative result be treated as an absolute guarantee that bacterial infection is absent.

The result must be considered in the context of:

the population in which the assay was validated,
pretest probability,
the patient's clinical presentation,
other diagnostic findings,
and the consequences of a false-negative result.

For stewardship purposes, the value is more specific.

In an appropriately selected patient with an uncertain respiratory presentation, a negative result may provide an additional objective data point supporting a decision not to prescribe an antibiotic when the total clinical assessment is consistent with that approach.

That matters because clinicians require confidence not only when prescribing antibiotics, but also when deciding not to prescribe them.

Stewardship Requires Confidence in the Non-Prescribing Decision

One of the practical difficulties in outpatient antibiotic stewardship is that withholding an antibiotic can be more psychologically and operationally difficult than prescribing one.

The clinician may be uncertain.

The patient may expect treatment.

Symptoms may be significant.

Follow-up may be imperfect.

There may be concern about an evolving bacterial process.

A clinician faced with uncertainty may therefore prescribe "just in case," even when bacterial infection is not strongly supported.

An objective result available during the encounter does not eliminate those considerations.

But it can add another clinically relevant piece of evidence to the decision.

That potentially changes the patient conversation as well.

Instead of relying only on:

"I don't think you need an antibiotic,"

the clinician can incorporate an objective host-response result into an explanation of why antibacterial therapy may not be indicated.

The test should not dictate that decision.

It can support it.

What the CLIA Waiver Changes

The CLIA waiver may be the most important implementation development in the evolution of FebriDx.

FebriDx can now be performed in appropriately authorized settings operating under a CLIA Certificate of Waiver. The assay does not require moderate- or high-complexity laboratory certification when performed under the applicable waived-testing framework.

That expands where the technology can potentially fit within a health system.

Depending on the organization's structure and the assay's labeling, appropriate environments may include:

primary care practices,
urgent care centers,
outpatient clinics,
physician offices,
emergency departments,
student health clinics,
and other qualified point-of-care environments operating under an appropriate CLIA framework.

The key point is not simply that the assay is easier to deploy.

It is that stewardship-supporting information can potentially be moved much closer to the locations where outpatient antibiotics are actually prescribed.

That creates a different implementation model.

CLIA-Waived Does Not Mean Oversight-Free

The term "CLIA-waived" can sometimes be misunderstood.

Waived status does not mean there are no operational responsibilities.

Organizations still need to establish appropriate processes for:

staff training,
adherence to the Instructions for Use,
quality-control procedures,
documentation,
result reporting,
site oversight,
and compliance with applicable CLIA and organizational policies.

The FebriDx implementation materials specifically describe external positive and negative controls and recommend quality-control testing with new lots, new shipments, and before a new operator performs patient testing. They also outline documentation and record-retention practices for inspection readiness.

This is important for stewardship and laboratory leadership.

The operational advantage of FebriDx is not that quality systems disappear.

It is that the assay can be incorporated into a waived-testing environment without an analyzer or moderate-complexity laboratory infrastructure.

From Retrospective Stewardship to Point-of-Decision Stewardship

Many antimicrobial stewardship interventions occur after prescribing behavior has already occurred.

Programs may analyze prescribing rates.

Review outliers.

Provide clinician education.

Issue guidelines.

Conduct audit and feedback.

Report antibiotic utilization by provider or site.

All of those interventions remain important.

But FebriDx creates the possibility of moving an additional stewardship intervention upstream.

A traditional retrospective pathway might look like:

Patient encounter → diagnostic uncertainty → antibiotic decision → prescribing data → stewardship review → feedback

A point-of-care pathway can potentially look more like:

Patient encounter → diagnostic uncertainty → host-response information → integrated clinical assessment → antibiotic decision

That does not replace traditional stewardship.

It supplements it.

The key difference is timing.

The intervention occurs before the prescription has been written.

The CLIA Waiver Creates a Decentralized Stewardship Opportunity

The more significant opportunity may not be implementation in a single clinic.

It may be deployment across an ambulatory network.

A health system might operate dozens—or hundreds—of locations where respiratory infections are evaluated and antibiotics are prescribed.

Historically, introducing a laboratory diagnostic broadly across those sites could require analyzers, capital investment, calibration, maintenance, connectivity, laboratory staffing, and more complex certification requirements.

FebriDx is self-contained and instrument-free. The implementation materials describe less than one minute of hands-on time, no analyzer, and no routine instrument calibration or maintenance.

CLIA-waived status therefore creates the possibility of deploying a standardized host-response tool across decentralized sites without placing an analyzer at each location.

For a health system pursuing enterprise-wide outpatient stewardship, that deserves consideration.

Antibiotic stewardship increasingly extends beyond the inpatient hospital.

The diagnostic tools supporting stewardship need to extend into those same environments.

Where FebriDx Might Fit in a Clinical Pathway

The most rational implementation is unlikely to involve indiscriminate FebriDx testing of every patient with respiratory symptoms.

A more disciplined strategy would identify where bacterial versus non-bacterial uncertainty is materially influencing treatment decisions.

One potential pathway might be:

Clinical assessment → pathogen-specific testing when clinically indicated → persistent bacterial/non-bacterial uncertainty → FebriDx in an eligible patient → integrated clinical decision

That sequence preserves the distinction between pathogen detection and host-response assessment.

The final step is also critical.

The FebriDx result is one component of the total clinical assessment.

It is not an autonomous treatment instruction.

The manufacturer explicitly positions FebriDx as a decision-support tool that complements clinical judgment rather than replacing it.

That is how an antimicrobial stewardship committee should evaluate it.

The Goal Is Better Antibiotic Use, Not Simply Fewer Antibiotics

Reducing unnecessary antibiotic exposure is a stewardship objective.

But a well-designed program should not define success simply as producing a lower prescribing rate.

The appropriate endpoint is:

Better antibiotic use without compromising patient safety.

That means any implementation should evaluate both stewardship outcomes and balancing measures.

A health system could examine:

antibiotic prescribing rates,
clinician-level prescribing variation,
guideline concordance,
subsequent bacterial diagnoses,
return encounters,
escalation of care,
emergency department utilization,
hospitalization,
provider acceptance,
patient understanding,
and workflow impact.

A reduction in antibiotics without appropriate safety monitoring would not constitute a complete stewardship evaluation.

The question is whether the diagnostic information improves decision quality.

Clinical Utility Must Be Demonstrated in Practice

Diagnostic performance alone does not establish clinical utility.

A test can perform well analytically and still have limited impact if:

clinicians do not trust the result,
ordering criteria are poorly defined,
results arrive after the treatment decision,
workflows are cumbersome,
or the result rarely changes management.

The CLIA waiver makes the clinical-utility question more relevant because FebriDx can now be moved more directly into the patient encounter.

The manufacturer describes the assay as requiring less than one minute of hands-on time, with the result available after approximately 10 minutes.

For implementation teams, the key operational question becomes:

Can the result reliably be available before the clinician makes the antibiotic decision?

If not, the clinical value of a rapid test may be substantially reduced.

What FebriDx Does—and Does Not—Tell the Clinician

A responsible stewardship implementation should define the limitations of the assay explicitly.

FebriDx does not identify a specific pathogen.

It does not eliminate the need for pathogen-directed testing when pathogen identification is clinically necessary.

It does not replace history, physical examination, imaging, microbiology, or other laboratory testing when indicated.

It does not establish severity of illness.

It does not mean every non-bacterial result should automatically lead to antibiotic avoidance.

And it should not be used outside its authorized intended-use population.

FebriDx provides another piece of host-response information for the clinician to integrate into the total clinical picture.

The manufacturer's compliance guidance appropriately prohibits claims that FebriDx diagnoses specific pathogens, replaces clinical judgment, eliminates other testing, guarantees reimbursement, or reduces antibiotic use in every case.

That restraint actually strengthens the clinical case.

The value proposition does not require overstating what the assay does.

A Stewardship Committee Should Evaluate FebriDx as a Clinical Intervention

The most productive question for a stewardship committee may not be:

"Should we add another respiratory test?"

It may be:

"Where in our system are clinicians making antibiotic decisions under avoidable diagnostic uncertainty, and could host-response testing improve those decisions?"

That leads naturally to a prospective evaluation.

A health system could identify high-volume respiratory settings, establish baseline prescribing patterns, define appropriate patient-selection criteria, implement FebriDx within a controlled workflow, and measure both stewardship outcomes and patient-safety outcomes.

Metrics Worth Measuring

A serious evaluation could include:

Antibiotic prescribing rate

Does antibiotic utilization change among appropriately selected FebriDx-tested patients?

Provider variation

Does access to objective host-response information reduce unwarranted variation between clinicians or sites?

Safety

Are there changes in repeat evaluation, delayed bacterial diagnoses, escalation of care, emergency department visits, hospitalization, or other clinically important balancing measures?

Diagnostic utilization

Does FebriDx affect use of pathogen testing, imaging, laboratory testing, or other diagnostics?

Workflow

Is the result consistently available before the treatment decision?

Clinician acceptance

Do clinicians believe the result improves decision-making in ambiguous cases?

Patient communication

Does objective testing help clinicians explain antibiotic-prescribing or non-prescribing decisions?

Guideline concordance

Does adoption improve alignment between prescribing behavior and the organization's stewardship protocols?

Those measures allow leadership to determine whether FebriDx is actually changing care—not merely whether the test is being ordered.

The Opportunity for Standardization

Another potential advantage for health systems is standardization.

Antibiotic decision-making can vary substantially between providers, locations, and shifts.

Some variation is clinically appropriate.

Some may reflect differences in tolerance for uncertainty.

A point-of-care host-response assay introduces the possibility of giving clinicians across multiple locations access to the same additional objective data.

That does not standardize medical judgment.

It may help standardize the information available to inform it.

For a stewardship program operating across a large ambulatory network, that distinction can be meaningful.

Why This Matters to the Chief Medical Officer

For a chief medical officer, FebriDx sits at the intersection of several priorities.

Clinical quality

Supporting more evidence-informed antibiotic decision-making.

Patient safety

Reducing avoidable antibiotic exposure while maintaining vigilance for bacterial disease.

Antimicrobial stewardship

Moving part of the stewardship intervention closer to the actual prescribing decision.

Clinical standardization

Providing a common diagnostic tool across decentralized sites where respiratory infections are treated.

Physician support

Giving clinicians additional objective information rather than simply asking them to change prescribing behavior.

Patient communication

Providing another evidence point that may help explain why an antibiotic is—or is not—appropriate.

Operational scalability

Deploying an instrument-free assay across waived-testing environments without requiring an analyzer at every site.

Most importantly, FebriDx represents a stewardship strategy that does not depend solely on policies, guidelines, or retrospective feedback.

It attempts to improve the information available at the point of care.

That is a fundamentally different intervention.

Why the CLIA Waiver Changes the Implementation Conversation

The biological premise of FebriDx did not change when the assay became CLIA-waived.

The stewardship problem did not change.

What changed was the practical ability to deploy the test across a broader range of point-of-care environments.

That matters because a diagnostic cannot influence a prescribing decision if it cannot practically be placed where the prescribing decision occurs.

CLIA-waived status allows FebriDx to be implemented under a Certificate of Waiver in authorized settings and removes the need for moderate- or high-complexity laboratory certification for this assay.

The result is a potentially different model of diagnostic stewardship:

not simply better testing inside the laboratory,

but clinically useful testing distributed across the healthcare system.

From Antibiotic Stewardship Policy to Diagnostic Stewardship Infrastructure

Antimicrobial stewardship has appropriately emphasized accountability, guidelines, education, audit and feedback, prescribing measurement, and clinician engagement.

The next stage may increasingly involve diagnostic stewardship infrastructure capable of delivering relevant information at the moment treatment decisions are made.

FebriDx represents one example of that evolution.

It does not solve every respiratory diagnostic question.

It does not identify the pathogen.

It does not replace the clinician.

It does not provide an automatic answer regarding antibiotic therapy.

Its potential value is narrower—and potentially important.

It provides an additional, rapidly available host-response signal intended to help differentiate bacterial acute respiratory infection from non-bacterial etiology while the patient is still being evaluated.

With CLIA-waived status reducing an important implementation barrier, healthcare organizations now have an opportunity to determine whether that information can improve antibiotic decision-making within their own clinical environments.

For CMOs and antimicrobial stewardship committees, the appropriate next step is not to assume that FebriDx will transform prescribing.

It is to evaluate whether it can—prospectively, rigorously, and with both stewardship and patient-safety outcomes measured.

That is how a diagnostic moves beyond simply being another test.

It becomes part of the clinical infrastructure supporting better decisions.

About FebriDx

The current product materials specify use in patients ages 12 through 64 presenting with symptoms of acute respiratory infection for less than seven days and within three days of fever onset.

About CG Moneta Consulting

CG Moneta Consulting works with healthcare organizations to evaluate and implement clinical, operational, financial, and technology solutions designed to improve healthcare delivery.

Through its strategic relationships, CGM supports healthcare organizations evaluating FebriDx and its potential role within point-of-care respiratory diagnostics and antimicrobial stewardship programs.

Clinical and Regulatory Note

FebriDx should be used in accordance with its FDA-cleared labeling and Instructions for Use. Results are intended to support—not replace—clinical judgment and should be interpreted in the context of the patient's presentation and other clinically appropriate diagnostic information. CLIA-waived sites remain responsible for applicable training, quality-control, documentation, oversight, and compliance requirements.

Selected References

Shapiro NI, Filbin MR, Hou PC, et al. Diagnostic Accuracy of a Bacterial and Viral Biomarker Point-of-Care Test in the Outpatient Setting. JAMA Network Open. 2022;5(10):e2234588. The FebriDx materials cite this multicenter study as supporting the assay's bacterial versus non-bacterial performance.

Lumos Diagnostics / PHASE Scientific Americas. FebriDx practitioner, clinical, regulatory, and CLIA-waived implementation materials.

U.S. Food and Drug Administration. FebriDx Bacterial/Non-bacterial Assay, 510(k) clearance K260787.

Centers for Disease Control and Prevention. Outpatient antibiotic stewardship and antimicrobial-resistance guidance.

The Employee Benefit That Matters Most When Life Doesn't Go as Planned

Sun, 13 Sep 2026 21:16:47 GMT

Why healthcare employers should consider giving employees access to permanent life insurance without the traditional medical review process—and why access itself may be one of the most valuable benefits an organization can provide.

Healthcare organizations devote significant resources to supporting their workforce.

Recruitment.

Retention.

Compensation.

Health insurance.

Retirement benefits.

Paid time off.

Professional development.

Employee wellness.

All are important.

But there is another question employers should consider:

If an employee dies unexpectedly, how financially prepared is the family left behind?

For many families, the answer may be uncomfortable.

Life insurance is one of those benefits whose importance can be easy to underestimate—until a family actually needs it.

For healthcare employers, the issue deserves particular consideration because there is an important difference between providing some workplace life insurance and giving employees meaningful access to long-term life insurance protection.

Those are not necessarily the same thing.

Workplace Life Insurance May Not Be Enough

Many organizations already provide basic group term life insurance.

That coverage can provide important protection.

But employer-sponsored term coverage does not necessarily address every family's long-term life insurance needs.

Coverage amounts may be limited.

Protection may be linked to employment.

Employees seeking additional coverage may need to enter the individual insurance market, where age, medical history, underwriting requirements, coverage amount, and other factors can influence availability and pricing.

This creates an important distinction for benefits leaders.

The question should not simply be:

“Do we offer life insurance?”

It should also be:

“Do our employees have access to protection that can address their individual circumstances?”

For some employees, obtaining additional individual coverage may be relatively straightforward.

For others, it may not be.

Employees Can Encounter Barriers to Obtaining Additional Coverage

Traditional individual life insurance underwriting can involve health questions, medical information, laboratory testing, or other forms of health assessment, depending on the insurer, product, applicant, and amount of coverage requested.

Health history can influence pricing, coverage availability, or insurability.

An employee may therefore understand the need for additional protection while still encountering barriers to obtaining it independently.

Healthcare employers have an opportunity to help address that access problem.

Through CG Moneta Consulting (CGM), participating healthcare organizations can introduce eligible employees to a MassMutual whole life insurance offering with a guaranteed-issue enrollment opportunity.

During the applicable enrollment opportunity, eligible employees may enroll without medical exams, health questionnaires, bloodwork, urine testing, or medical interviews, subject to program requirements, eligibility, enrollment timing, coverage limits, and policy terms.

That changes the nature of the benefit.

It is not simply another insurance option.

It is expanded access.

Access May Be the Most Important Feature

Consider two employees.

One may be able to obtain individual life insurance relatively easily.

Another may have a health history that could make traditional individual underwriting more challenging.

Both may have spouses.

Both may have children.

Both may have mortgages, household expenses, educational obligations, or family members who depend upon their income.

Their need for financial protection may be similar.

Their ability to obtain it through the individual market may not be.

A workplace benefit that reduces traditional medical-review barriers can therefore have particular value for eligible employees who might otherwise encounter challenges obtaining additional coverage.

That is what makes the guaranteed-issue opportunity different from simply adding another voluntary benefit to an enrollment menu.

For some employees, the workplace may provide access to an option that could be difficult to replicate independently.

A 40% Group-Rate Advantage Changes the Economics

Access is only part of the equation.

Affordability matters as well.

The MassMutual offering available through CGM is structured with an approximately 40% group discount compared with certain standard individual whole life premiums for comparable coverage, subject to program and policy terms.

That distinction matters because this is permanent whole life insurance rather than basic term-only workplace coverage.

Whole life insurance is designed to remain in force when required premiums are paid and applicable policy provisions are satisfied.

It also includes a cash-value component, although employees should review both guaranteed and non-guaranteed policy elements carefully and evaluate the coverage based on their individual circumstances.

The combination is what makes the offering unusual:

Permanent whole life protection.

Reduced traditional medical-review barriers during the applicable guaranteed-issue enrollment opportunity.

An approximately 40% group-rate advantage compared with certain comparable individual whole life premiums.

Portability beyond employment.

Each feature has value individually.

Together, they create a benefit that may be difficult for some employees to replicate in the individual marketplace.

Portability Matters in a Mobile Healthcare Workforce

Healthcare professionals change employers.

Nurses move between hospitals.

Physicians change health systems.

Employees relocate.

Organizations merge.

People retire.

A life insurance benefit tied exclusively to employment can therefore create a potential coverage issue when the employment relationship ends.

The whole life offering available through CGM is designed to be portable. Coverage may remain with the employee after changing jobs or retiring, subject to the terms of the issued policy.

That changes the nature of the benefit.

The employer provides the opportunity.

The employee owns coverage that may continue beyond that employee's tenure with the organization, provided applicable policy requirements are satisfied.

For a mobile workforce, that distinction can be important.

The Employer Does Not Have a Direct Premium Obligation

One of the most important aspects of the program from the employer's perspective is its voluntary structure.

The offering can be introduced as an employee-paid benefit with no direct employer premium obligation.

Eligible employees decide whether participation makes sense based on their family needs, financial circumstances, budget, and coverage preferences.

The employer provides access.

The employee makes the decision.

That creates an unusual benefits equation:

Potentially meaningful employee value without requiring the organization to assume the employee's insurance premium.

This does not mean implementation requires no employer involvement. Leadership still needs to evaluate the program, coordinate rollout, and facilitate appropriate administrative processes such as payroll deduction.

But not every enhancement to an employee benefits package requires the employer to fund another insurance premium.

Sometimes value can be created by expanding access.

The Benefit Can Extend Beyond the Death Benefit

The program also includes policy-governed rider features, including waiver of premium, accidental death, chronic care, and terminal illness riders.

These features are subject to the terms, conditions, eligibility requirements, limitations, exclusions, and provisions of the issued policy.

They reinforce an important point.

Life insurance should not necessarily be evaluated solely by asking what happens upon the insured's death.

Depending upon the policy and qualifying circumstances, certain rider provisions may provide benefits during the insured's lifetime.

Employees should review these provisions carefully and understand when and how they apply.

Benefits Remain an Important Part of the Employee Value Proposition

Employee benefits continue to influence how workers evaluate their employers.

Current LIMRA research finds that roughly two-thirds of workers say their benefits make them more inclined to remain with their current employer. LIMRA also reports that workplace benefits remain among the leading factors employees consider when evaluating employment opportunities.

That does not mean adding a life insurance option will independently solve recruitment or retention challenges.

It means benefits are one component of the broader employment relationship.

Employees evaluate more than salary.

They consider health insurance.

Retirement benefits.

Paid leave.

Financial protection.

Flexibility.

Work environment.

And the range of benefits available to them.

A differentiated voluntary benefit can contribute to that overall employee value proposition, particularly when it addresses a need employees may have difficulty solving independently.

There Is a Difference Between Providing a Benefit and Providing Access

An employer can provide basic life insurance and still have employees whose individual protection needs exceed the amount available through the employer-paid plan.

An employer can offer voluntary supplemental coverage and still have employees who encounter underwriting limitations under other forms of coverage.

And an employee can understand the importance of life insurance while postponing it because the individual purchase process appears expensive, complicated, or uncertain.

A workplace program can help remove some of those barriers.

The value of the offering therefore should not be measured solely by enrollment.

The employer is providing something more fundamental:

an opportunity for eligible employees to evaluate additional permanent protection under terms they may not otherwise have available to them.

Education Is Essential

Life insurance is a financial product.

It should not be presented to employees as something they automatically need to purchase.

Employees have different family structures, incomes, existing insurance, financial obligations, budgets, health circumstances, and long-term objectives.

The appropriate role of the employer is not to tell employees what to buy.

It is to provide access and education.

CGM supports participating employers with onsite educational presentations, employee Q&A, enrollment coordination, and complimentary lunch-and-learn sessions.

Employees can learn how the coverage works, review available options, ask questions, and decide whether participation is appropriate for their individual circumstances.

That educational component is particularly important when discussing permanent life insurance because employees should understand both the benefits and the ongoing premium commitment associated with maintaining coverage.

The Carrier Behind the Promise Matters

Life insurance represents a long-term contractual commitment.

The financial strength of the company making that commitment therefore matters.

The program is issued through MassMutual, a mutual life insurance company founded in 1851.

MassMutual currently reports financial-strength ratings of:

A++ from AM Best — Superior

AA+ from Fitch Ratings — Very Strong

Aa3 from Moody's Investors Service — High Quality

AA+ from S&P Global Ratings — Very Strong

Ratings are subject to change, apply to the applicable issuing companies, and are not recommendations to purchase insurance or indications of investment performance.

Any policy guarantees depend upon the claims-paying ability of the issuing insurance company.

For employees considering coverage that may remain in force for decades, the financial strength and operating history of the carrier are relevant considerations.

A Simple Question for Healthcare Leadership

For a hospital CEO, CHRO, CFO, or benefits leader, the decision does not have to begin with whether every employee should purchase whole life insurance.

That is an individual decision.

The organizational question is simpler:

Should eligible employees have the opportunity to evaluate it?

If an organization can potentially give eligible employees access to:

Permanent whole life insurance,

without medical exams, health questionnaires, bloodwork, urine testing, or medical interviews during the applicable guaranteed-issue enrollment opportunity,

at an approximately 40% group discount compared with certain standard individual whole life premiums for comparable coverage,

with portable coverage designed to remain with the employee after a job change or retirement, subject to policy terms,

and without requiring the employer to assume the employee's premium obligation,

then it may be worth determining whether the benefit fits the workforce.

Employees can decide whether to participate.

But they cannot evaluate an opportunity they were never given.

Sometimes the Most Valuable Benefit Is Access

Healthcare organizations devote enormous resources to caring for patients.

The people delivering that care have financial protection needs of their own.

Not every employee will need the same amount or type of life insurance.

Not every eligible employee will choose to participate.

And no single benefit will solve the broader challenges of workforce satisfaction, retention, or financial wellness.

But certain benefits can be valuable precisely because they provide access to something that may otherwise be difficult for an employee to obtain.

For one employee, this offering may simply provide another option to consider.

For another who has encountered traditional underwriting barriers, the access may carry considerably greater significance.

And for a family that eventually depends upon the coverage, the value may be greater still.

The most valuable employee benefits are not always the ones an employer spends the most to provide.

Sometimes they are the opportunities an employer makes possible.

About CG Moneta Consulting

CG Moneta Consulting works with healthcare organizations to identify and evaluate financial, operational, technology, workforce, and innovation opportunities capable of creating measurable value.

Through its group life insurance offering, CGM helps healthcare employers evaluate access to a MassMutual whole life insurance program and supports implementation through employee education, onsite presentations, Q&A, enrollment coordination, and payroll-deduction coordination.

Availability, eligibility, coverage amounts, riders, guaranteed-issue provisions, enrollment periods, pricing, and state-specific provisions are subject to applicable program and policy terms. Guaranteed-issue availability is subject to applicable enrollment periods and program requirements. Employees should review issued policy materials carefully and consider their individual circumstances before electing coverage. Whole life insurance contains a cash-value component, but this information should not be interpreted as investment, legal, tax, accounting, or financial-planning advice. Any policy guarantees are based on the claims-paying ability of the issuing insurance company.

Healthcare Doesn't Need More Vendors. It Needs Better Solutions.

Sun, 13 Sep 2026 21:04:01 GMT

Why a vendor-agnostic approach helps healthcare leaders filter market noise, allocate resources more effectively, and focus on opportunities capable of creating measurable value.

Healthcare organizations do not suffer from a lack of solutions.

If anything, the opposite is true.

Hospital and health system executives are continually approached by technology companies, consultants, revenue cycle firms, cost-reduction specialists, artificial intelligence platforms, clinical technology companies, outsourcing organizations, and other vendors promising to improve some aspect of performance.

The challenge is no longer simply finding solutions.

The challenge is determining which solutions are actually worth pursuing.

Every new initiative competes for executive attention, financial resources, IT capacity, legal review, clinical involvement, implementation resources, and organizational bandwidth.

Even a potentially valuable solution can become a distraction if the opportunity is poorly understood, improperly timed, difficult to implement, or insufficiently aligned with the organization's priorities.

Healthcare leaders therefore face an increasingly important question:

How do you separate meaningful opportunities from market noise?

That question is at the center of why CG Moneta Consulting (CGM) was created.

Healthcare Has an Opportunity-Selection Problem

The healthcare marketplace has become extraordinarily complex.

A CFO may simultaneously be evaluating reimbursement performance, revenue cycle initiatives, labor expense, pharmacy economics, vendor contracts, capital requirements, technology investments, and cost-containment strategies.

A CIO may be considering cybersecurity, cloud infrastructure, telecommunications, interoperability, artificial intelligence, automation, and dozens of other competing technology priorities.

Clinical leadership may be evaluating diagnostic technologies, workflow tools, patient-access initiatives, clinical decision support, and innovations intended to improve quality or efficiency.

Many of these opportunities may have merit.

But organizations cannot pursue everything.

The scarce resource is often not access to ideas.

It is organizational attention .

Every initiative placed in front of an executive team carries an opportunity cost. Time spent evaluating one project is time that cannot be spent evaluating another. Capital committed to one initiative cannot be deployed elsewhere. IT resources assigned to one implementation may delay something more important.

This makes opportunity selection itself a strategic discipline.

The question is not simply:

“Is this a good solution?”

It is:

“Is this the right solution for this organization, at this time, relative to the other opportunities competing for the same resources?”

Those are very different questions.

The Traditional Vendor Model Starts With the Product

Most vendors understandably approach the market from the perspective of what they sell.

A cybersecurity company sees cybersecurity problems.

A revenue cycle company sees revenue cycle problems.

A telecommunications company sees telecommunications opportunities.

An AI company sees opportunities for artificial intelligence.

That does not mean those companies lack valuable solutions.

It means their perspective is naturally shaped by the capability they provide.

The healthcare organization, however, has to look across the entire enterprise.

Its responsibility is not merely to determine whether a particular vendor has a compelling product.

Its responsibility is to determine where the next dollar, the next hour of executive attention, and the next implementation resource can create the greatest organizational value.

That requires a different perspective.

Start With the Problem, Not the Product

CGM begins from the opposite direction.

Rather than starting with a predetermined product and searching for an organization to purchase it, the advisory process should begin with the provider's problem, objective, or opportunity.

Where is revenue being lost?

Where are recurring expenses unnecessarily high?

Where might reimbursement performance be falling short?

Where are technology investments failing to produce sufficient value?

Which emerging technologies deserve serious consideration?

Which financial incentives may be overlooked?

Where can existing processes be strengthened without disrupting operations?

Where does a specialized capability exist that leadership may not otherwise encounter?

Only after the opportunity is understood should the potential solution become the focus.

That philosophy is the foundation of a vendor-agnostic approach.

For CGM, vendor-agnostic does not mean operating without solution partners. It means beginning with the client's objective rather than assuming in advance that a specific partner or product must be the answer.

Sometimes the right conclusion may be to implement a new solution.

Sometimes it may be to optimize an existing relationship.

Sometimes it may be to compare several alternatives.

And sometimes the appropriate recommendation may be to do nothing.

That last possibility matters.

Independence has limited value if every evaluation inevitably produces another project.

A Financial-Services Perspective Applied to Healthcare

That philosophy is not accidental.

It reflects the professional backgrounds of CGM's Managing Partners.

Both came to CGM from careers rooted in financial services and banking.

Daniel Covell began his career with Morgan Stanley in New York City and later built a private wealth management practice, spending more than two decades in financial services and business leadership.

Vincent Gargione brought more than twenty years of experience spanning banking, financial management, executive leadership, client advisory, healthcare, sales leadership, and business development.

Those backgrounds shaped how CGM evaluates healthcare opportunities.

In financial services, a sophisticated advisor does not begin with:

“What product can I sell?”

The process should begin with:

“What is the objective?”

What resources are available?

What are the risks?

What alternatives exist?

What is the expected return?

How does the opportunity fit within the broader strategy?

What happens if circumstances change?

And, perhaps most importantly:

Is taking action actually better than maintaining the status quo?

That discipline translates naturally to healthcare.

A hospital may have hundreds of potential initiatives available to it.

But just as an investment portfolio should not be constructed by purchasing every investment that appears attractive individually, an organization's strategic portfolio should not be constructed by pursuing every vendor opportunity that promises a positive outcome.

Individual opportunities have to be evaluated in the context of the whole organization.

In both financial services and healthcare, capital is finite. The responsibility is not simply to find opportunities—it is to steward resources toward the opportunities most capable of creating value.

Healthcare Decisions Should Be Viewed as a Portfolio

Consider the number of areas competing for resources within a healthcare organization:

Revenue recovery.

Revenue cycle performance.

Payer reimbursement.

Operating expense.

Pharmacy economics.

Technology infrastructure.

Cybersecurity.

Cloud services.

Telecommunications.

Artificial intelligence.

Clinical innovation.

Patient access.

Workflow automation.

Specialized financial incentives.

Capital investment.

Each may represent a legitimate opportunity.

But they do not exist independently.

A technology project affects capital allocation.

A revenue initiative may require IT resources.

A clinical technology may require workflow changes.

A cost-reduction initiative may affect an existing vendor relationship.

An innovation project may require legal, compliance, clinical, IT, and financial review before implementation.

The organization therefore needs more than individual vendor evaluations.

It needs a way to evaluate opportunities as a portfolio of competing investments in organizational performance.

The goal is not to accumulate more opportunities.

It is to allocate limited resources toward those most likely to create meaningful value.

A Disciplined Evaluation Framework

CGM organizes that process around five stages:

Identify

Determine where financial, operational, technology, incentive, or innovation opportunities may exist.

Evaluate

Assess the evidence, economics, risks, implementation requirements, and potential value.

Align

Determine whether the opportunity fits organizational priorities, timing, available resources, and stakeholder requirements.

Implement

Define scope, responsibilities, milestones, and measures of success.

Measure

Determine whether the initiative produced the financial, operational, clinical, or strategic value expected.

The purpose of this framework is not to make every opportunity move forward.

It is to make better opportunities move forward for better reasons.

Specialized Solutions Can Be Difficult to Discover

Some of the most valuable capabilities in healthcare are not necessarily offered by the largest or most recognizable companies.

Innovation is increasingly distributed across specialized organizations developing highly focused technologies and services.

One company may have exceptional expertise in a narrow area of reimbursement.

Another may have developed a diagnostic technology addressing a specific clinical problem.

Another may specialize in identifying hidden operating expense.

Another may solve a particular interoperability, pharmacy, technology, or administrative challenge.

These organizations may have meaningful capabilities but lack the enormous sales infrastructure necessary to reach every hospital or health system that could benefit from them.

At the same time, healthcare executives cannot reasonably evaluate thousands of emerging companies themselves.

This creates an information asymmetry on both sides of the market.

Promising companies struggle to reach the appropriate decision-makers.

Healthcare organizations struggle to distinguish genuinely differentiated capabilities from the enormous volume of companies competing for their attention.

An effective advisory firm can serve as a filter between the two.

Curation Matters More as Innovation Accelerates

This filtering function becomes increasingly important as healthcare innovation accelerates.

Artificial intelligence is a good example.

Healthcare executives are now presented with an extraordinary number of companies describing their products as AI-enabled.

But “uses artificial intelligence” is not an investment thesis.

Leadership still has to ask:

What problem does it solve?

Is the problem significant?

What evidence supports the technology?

Is it clinically or operationally relevant?

How difficult is implementation?

Does it integrate into existing workflows?

What resources will it require?

What are the regulatory considerations?

What measurable value should the organization expect?

Is the company capable of supporting enterprise deployment?

And how does the opportunity compare with other initiatives competing for the same resources?

Innovation becomes valuable only when it solves a real problem.

That is why CGM's approach to emerging healthcare solutions emphasizes provider relevance, differentiation, implementation readiness, organizational credibility, evidence, and measurable value before a capability merits serious consideration.

Not Every Opportunity Should Advance

A disciplined evaluation process must be capable of reaching several different conclusions.

This deserves immediate attention.

This deserves further diligence.

This is potentially valuable, but the timing is wrong.

This does not fit the organization's priorities.

This duplicates an existing capability.

The economics are insufficient.

The implementation burden outweighs the likely benefit.

Or simply:

This is not worth pursuing.

The ability to say no is as important as the ability to identify an opportunity.

If every product, technology, or service ultimately becomes a recommendation, there is no meaningful filtering process.

A strong advisory relationship should reduce noise, not add to it.

Measurable Value Should Be the Common Language

Healthcare initiatives can differ dramatically.

A reimbursement audit and an AI diagnostic platform may appear to have very little in common.

A cloud infrastructure project and a pharmacy initiative may involve completely different stakeholders.

An expense-reduction project and a clinical technology may require entirely different implementation processes.

But they can still be evaluated through a common framework.

What problem are we solving?

What is the expected value?

What resources are required?

What risks are involved?

How will implementation affect the organization?

How will success be measured?

The answer may be financial.

It may be operational.

It may be clinical.

It may involve risk reduction, infrastructure resilience, patient access, workflow efficiency, or organizational capacity.

But there should be an identifiable reason for committing resources.

“Interesting technology” is not enough.

“Potential savings” is not enough.

“Artificial intelligence” is not enough.

“Industry-leading” is not enough.

Healthcare organizations should expect opportunities to survive disciplined scrutiny before they consume organizational resources.

The Best Solution May Already Be Inside the Organization

Vendor-agnostic thinking also requires acknowledging something that is often overlooked:

A healthcare organization may already possess the capability necessary to solve the problem.

A new vendor should not automatically be the answer.

Sometimes the opportunity is to improve utilization of existing technology.

Sometimes existing contract terms should be renegotiated.

Sometimes the organization needs independent validation of current performance rather than replacement of an incumbent vendor.

Sometimes a specialized solution can operate alongside an existing platform rather than displacing it.

And sometimes internal processes can be improved without adding another external relationship.

The objective should be problem resolution, not vendor accumulation.

Independence Creates a Different Conversation

When an advisory relationship begins without the assumption that a particular product must be sold, the conversation with healthcare leadership changes.

Instead of:

“Would you like to see our solution?”

The conversation becomes:

“Where are you experiencing pressure?”

Where might performance be falling short?

Which initiatives are currently competing for attention?

What has already been attempted?

What constraints exist?

What would meaningful improvement look like?

Only then does the discussion move toward possible solutions.

That sequence matters because the quality of the recommendation is often determined by the quality of the problem definition.

Executive Attention Is Capital

Healthcare organizations carefully manage financial capital.

Executive attention deserves similar discipline.

Every vendor evaluation.

Every pilot.

Every legal review.

Every IT integration.

Every implementation.

Every new initiative placed on a leadership agenda consumes organizational capacity.

That capacity is finite.

The responsibility of an advisory firm should therefore not be to create more activity.

It should be to improve the quality of the activity that occurs.

A valuable advisor should help leadership determine:

What deserves attention?

What does not?

What should happen now?

What should wait?

And where can the organization create the greatest measurable value with the resources available?

Why CGM Exists

CGM was built around a simple belief:

Healthcare organizations do not need another source of vendor noise. They need a clearer way to evaluate opportunity.

CGM is a vendor-agnostic healthcare consulting and advisory firm focused on helping providers evaluate financial, operational, technology, incentive, and innovation opportunities.

The firm's role is not to convince healthcare leaders that every solution is necessary.

It is to help determine which opportunities are credible, relevant, practical, and capable of producing measurable value.

That may involve identifying hidden revenue.

Reducing recurring expense.

Evaluating technology.

Assessing emerging healthcare innovation.

Identifying specialized financial opportunities.

Connecting providers with highly specialized expertise.

Validating whether existing processes or vendor relationships are performing as expected.

Or determining that an opportunity should not move forward at all.

The specific solution may change.

The evaluation philosophy should not.

Better Decisions Before Bigger Commitments

Healthcare will continue to become more complex.

Artificial intelligence will accelerate.

New diagnostic technologies will emerge.

Reimbursement will evolve.

Technology infrastructure will become increasingly critical.

Financial pressure will remain.

Specialized companies will continue developing capabilities that established healthcare organizations may never discover through traditional procurement channels.

Healthcare leaders will therefore have more options—not fewer.

The competitive advantage will not come from knowing about every available solution.

It will come from developing the discipline to identify which opportunities matter.

That requires independent judgment.

Financial discipline.

Operational awareness.

Clinical context.

Objective evaluation.

Implementation realism.

And a willingness to say no when the opportunity does not justify the resources required.

Healthcare doesn't need more vendors simply because more vendors exist.

It needs better solutions—and a disciplined way to determine which ones deserve the organization's time, capital, and attention.

About CG Moneta Consulting

CG Moneta Consulting is a vendor-agnostic healthcare consulting and advisory firm that helps healthcare organizations evaluate financial, operational, technology, incentive, and innovation opportunities. CGM works with healthcare leaders to identify areas of potential value, evaluate specialized solutions, align opportunities with organizational priorities, support implementation, and maintain focus on measurable outcomes.

CGM's advisory philosophy is influenced by the financial-services and banking backgrounds of its Managing Partners and is built around disciplined evaluation, responsible stewardship of organizational resources, and the belief that better decisions should precede bigger commitments.

Beyond the Waveform: How AI Is Expanding the Diagnostic Potential of the 12-Lead ECG

Sun, 13 Sep 2026 20:47:55 GMT

How deep learning is transforming the 12-lead ECG into a high-dimensional tool for detecting structural and functional cardiac phenotypes.

A routine 10-second ECG contains tens of thousands of digital measurements. Deep learning is beginning to demonstrate that those signals may encode clinically meaningful information about cardiac structure and function that extends beyond conventional electrocardiographic interpretation.

For more than a century, the 12-lead electrocardiogram has been foundational to cardiovascular medicine.

Its traditional diagnostic utility is well established: rhythm and conduction abnormalities, repolarization disturbances, chamber abnormalities, ischemic changes, infarction patterns, and numerous other electrophysiologic findings.

What is changing is not the ECG acquisition itself.

It is the analytical depth that can be applied to the underlying signal.

Artificial intelligence—particularly deep learning—allows the raw digital ECG waveform to be interrogated at a dimensionality that conventional visual interpretation cannot practically reproduce.

Rather than asking only whether an ECG demonstrates a recognized abnormality, AI-enabled electrocardiography introduces a different question:

Can the electrical phenotype contain reproducible signatures of structural or functional cardiovascular disease that are not readily apparent through conventional ECG interpretation?

An expanding body of research suggests that, for certain phenotypes, it can.

That possibility could fundamentally broaden the role of one of medicine's oldest diagnostic technologies.

The ECG as a High-Dimensional Physiologic Dataset

The familiar ECG tracing represents only the visual expression of a much larger numerical dataset.

Medical AI's AiTiA platform analyzes the raw digital ECG signal rather than relying solely on an image of the tracing.

At a sampling frequency of 500 Hz, each lead generates 500 numerical measurements per second.

Across a standard 10-second, 12-lead acquisition:

500 samples/second × 10 seconds × 12 leads = 60,000 numerical data points.

Medical AI's technical materials specifically identify these 60,000 raw measurements as the input available for AI analysis.

Conventional interpretation reduces this information into clinically meaningful constructs: rhythm, rate, intervals, axis, voltage, morphology, conduction, depolarization, repolarization, and recognized patterns of disease.

Deep-learning models are not necessarily constrained to those predefined features.

They can learn latent representations within the raw waveform—complex combinations of temporal, morphologic, amplitude, and interlead relationships statistically associated with a defined clinical phenotype.

Some of these representations may overlap with electrocardiographic features clinicians already recognize.

Others may be distributed across the waveform and not readily reducible to conventional human-interpretable ECG criteria.

This is the fundamental premise underlying AI-ECG.

Connecting the Electrical Phenotype to the Echocardiographic Phenotype

Left ventricular systolic dysfunction provides an instructive example.

An ECG does not directly measure ejection fraction.

Echocardiography does.

For an AI-ECG model targeting LV systolic dysfunction, ECG recordings can be paired with a reference phenotype established by cardiac imaging.

The model is then trained to identify features within the electrical signal associated with the imaging-defined phenotype.

In simplified terms:

Echocardiography establishes the cardiac phenotype.
The ECG provides the electrical phenotype.
Deep learning identifies statistical relationships between the two.

For AiTiA LVSD, Medical AI defines the target phenotype as LVEF ≤40%.

The algorithm therefore does not "calculate" LVEF from an ECG in the manner that an echocardiographic measurement is obtained.

Nor does it create a surrogate echocardiographic image.

It identifies an ECG-derived probability signal associated with the presence of an echo-defined ventricular phenotype.

That distinction is critical to interpreting both the capabilities and limitations of the technology.

Why Should LV Dysfunction Produce an AI-Detectable Electrical Phenotype?

The biological premise is plausible because myocardial structure, ventricular function, and cardiac electrophysiology are interdependent.

Ventricular remodeling, fibrosis, changes in myocardial mass, altered loading conditions, ischemic injury, neurohormonal effects, conduction disturbances, and changes in myocardial function can affect depolarization and repolarization.

Some resulting manifestations are already recognized clinically.

Others may produce far more subtle alterations in waveform morphology, timing, amplitude, and interlead relationships.

A deep-learning architecture can interrogate those relationships simultaneously across the full digital waveform.

The model is therefore not visualizing mechanical dysfunction.

It is detecting a high-dimensional electrical phenotype statistically associated with it.

This distinction is one reason AI-ECG may be better conceptualized as an ECG-derived digital biomarker rather than as an alternative imaging modality.

AiTiA LVSD: Identifying Reduced LV Systolic Function From the 12-Lead ECG

Medical AI's AiTiA LVSD algorithm is designed to identify patients with left ventricular systolic dysfunction using a routine digital 12-lead ECG.

The target condition described in Medical AI's clinical materials is LVEF ≤40%, corresponding to clinically significant reduced LV systolic function.

The acquisition remains a standard 10-second ECG.

The raw waveform is analyzed by the AI model.

The software generates a continuous 0–100 risk score and risk classification that can be incorporated into the existing ECG-reporting workflow.

No additional physiologic acquisition is required simply to generate the AI analysis.

That creates an important distinction between AI-ECG and many other diagnostic technologies.

The diagnostic input remains familiar. The analytical depth changes.

What Does the Clinical Validation Show?

Medical AI's pivotal clinical materials report a single-center study involving 688 participants, with approximately 15% prevalence of LV systolic dysfunction.

Reported performance included:

AUROC: 0.919

Positive predictive value: 0.715

Negative predictive value: 0.982

Medical AI also reports subgroup analyses across age, sex, and medical history, with performance remaining robust within the evaluated subgroups.

In a subgroup for whom NT-proBNP results were available, the company's pivotal-study analysis reported an AUROC of 0.905 (95% CI, 0.842–0.968) for AiTiA LVSD compared with 0.720 (95% CI, 0.635–0.804) for NT-proBNP.

That comparison is potentially interesting, but it should be interpreted cautiously. It represents a smaller subgroup and does not establish AI-ECG as a replacement for natriuretic peptide testing.

More broadly, peer-reviewed evidence in the AI-ECG field supports the feasibility of identifying reduced ventricular systolic function from the 12-lead ECG.

The clinical question, however, extends beyond discrimination.

For physicians considering how such technology could actually be deployed, AUROC is only the beginning.

What the AI-ECG Result Does—and Does Not Mean

A positive AiTiA LVSD result does not directly measure LVEF.

It does not establish a diagnosis of heart failure.

It does not characterize ventricular morphology.

And it does not replace echocardiography when definitive assessment of cardiac structure and function is clinically indicated.

The model generates an ECG-derived risk signal associated with the target phenotype of LVEF ≤40%.

Its interpretation therefore depends on clinical context.

That includes:

Pretest probability
Symptoms and functional status
Known cardiovascular disease
Comorbidities
Physical examination
Prior ECG findings
Natriuretic peptide data when appropriate
Previous cardiac imaging
The prevalence of LV dysfunction in the population being evaluated
The clinical consequences of false-positive and false-negative results

The prevalence issue is particularly important.

PPV and NPV are not intrinsic characteristics of an algorithm independent of the population in which it is used.

In a low-prevalence screening population, an algorithm can maintain excellent discrimination, sensitivity, and specificity while producing a substantially lower PPV.

In a higher-risk population, the predictive-value profile may be very different.

The clinically meaningful question is therefore not simply:

"What is the AUROC?"

It is:

"Does the algorithm identify the appropriate patients for definitive evaluation, with an acceptable false-positive and false-negative burden, in the population in which it is being deployed?"

That is the standard against which AI-ECG should ultimately be evaluated.

The Appropriate Clinical Role Is Triage, Not Echocardiographic Replacement

At present, the most clinically coherent role for AI-ECG is not as a replacement for echocardiography.

It is as an additional layer of screening, risk stratification, or diagnostic triage.

Echocardiography provides direct structural and functional information that an ECG cannot.

AI-ECG addresses a different problem:

Can a rapidly acquired, widely available physiologic signal identify patients whose probability of ventricular dysfunction is sufficiently elevated to warrant definitive assessment?

Conceptually, the pathway becomes:

Routine 12-lead ECG → AI-derived probability signal → targeted echocardiography or additional evaluation when clinically appropriate.

This distinction has practical significance.

Population-wide echocardiographic screening is resource intensive.

ECGs, by contrast, are already acquired at enormous scale across healthcare.

If AI can extract a validated ventricular dysfunction signal from an ECG that has already been obtained, the technology could create a low-incremental-burden mechanism for identifying patients who might otherwise not undergo imaging.

The objective is not necessarily to perform more echocardiograms.

It is potentially to identify more effectively which patients should receive them.

A Normal-Looking ECG May Not Be Data-Normal

One of the more provocative implications of AI-ECG is that a tracing can appear relatively unremarkable by conventional visual criteria while still contain a disease-associated signal.

Human ECG interpretation relies on recognizable constructs:

Rate.

Rhythm.

PR interval.

QRS duration.

QT interval.

Axis.

Voltage.

Conduction.

ST-T morphology.

Q waves.

Hypertrophy patterns.

An AI model is not restricted to those constructs.

It can evaluate nonlinear interactions distributed across tens of thousands of numerical measurements.

A patient therefore may lack an obvious human-interpretable ECG signature of LV systolic dysfunction while still producing a waveform containing features that contribute to an elevated model output.

This is both scientifically compelling and clinically challenging.

The inability to reduce every model output to a recognizable ECG feature increases the importance of:

External validation.

Calibration.

Population-specific performance.

Prospective evaluation.

Clearly defined intended use.

Workflow integration.

Post-deployment performance monitoring.

The more powerful the inference becomes, the more rigorous the validation must be.

From a Single Algorithm to a Multi-Phenotype AI-ECG Platform

LV systolic dysfunction represents only one potential application.

Medical AI's broader research program describes AI-ECG investigation across multiple cardiovascular and systemic phenotypes, including:

Left ventricular systolic dysfunction
Left ventricular diastolic dysfunction
Valvular heart disease
Pulmonary hypertension
STEMI and NSTEMI
Atrial fibrillation prediction
Anemia and electrolyte abnormalities
Cardiac arrest risk

Medical AI's research materials describe published work across this broader spectrum of cardiovascular and systemic conditions.

Its current development pipeline also includes additional disease-specific AI-ECG applications.

This creates an important conceptual distinction.

AiTiA can be viewed not simply as a single LVSD-detection algorithm, but as a potential multi-phenotype AI-ECG platform architecture.

The underlying physiologic input can remain largely unchanged:

a digital 12-lead ECG waveform.

What changes is the independently developed, validated, and appropriately authorized algorithm applied to that waveform.

Additional Indications Could Fundamentally Change the Role of the ECG

Medical AI intends to continue developing additional AI-ECG indications and pursuing the applicable regulatory pathways for clinical use.

Each indication must be evaluated independently.

Performance for LV systolic dysfunction does not establish validity for acute myocardial infarction, aortic stenosis, diastolic dysfunction, pulmonary hypertension, arrhythmia prediction, or another phenotype.

Each clinical application requires its own evidence base, appropriate validation, defined intended-use population, performance characteristics, and applicable regulatory authorization.

But the architecture becomes particularly interesting if multiple disease-specific models ultimately satisfy those requirements.

A single 10-second, 12-lead acquisition could potentially serve as the input for multiple independently validated analytical models.

The same underlying electrical dataset could potentially be interrogated for signatures associated with:

Ventricular systolic function.

Diastolic dysfunction.

Valvular disease.

Myocardial ischemia or injury.

Pulmonary vascular disease.

Future arrhythmic risk.

Other cardiovascular or systemic phenotypes.

The sophistication would not come from making the physical ECG acquisition more complicated.

Quite the opposite.

The acquisition could remain remarkably simple while the computational interpretation becomes increasingly complex.

If multiple independently validated indications ultimately receive appropriate regulatory authorization and can be integrated into a unified clinical platform, AI-ECG could evolve into an unusually sophisticated form of multi-phenotype cardiovascular decision support built on a single physiologic recording.

A Different Model of Diagnostic Technology

Most diagnostic technologies are closely linked to a specific measurement.

Echocardiography generates structural and functional imaging.

Cardiac troponin measures a circulating biomarker associated with myocardial injury.

CT provides cross-sectional anatomical information.

The potential architecture of a multi-indication AI-ECG platform is different.

One physiologic dataset can potentially serve as the input for multiple specialized analytical models.

The physical test does not necessarily have to change when another validated algorithm becomes available.

The analytical layer changes.

This has potentially important implications for clinical scalability.

A healthcare organization does not necessarily need to introduce an entirely new diagnostic acquisition for each AI phenotype.

Instead, additional clinical intelligence may potentially be extracted from a physiologic signal already being collected.

That shifts the paradigm from:

one test → one principal interpretation

toward:

one physiologic signal → multiple independently validated clinical inferences.

That is a fundamentally different way of thinking about the ECG.

Could the AI Score Function as a Longitudinal Digital Biomarker?

Medical AI's research also raises another clinically interesting possibility: whether serial AI-ECG scores may provide information about changes in ventricular function over time.

The company's materials describe cases in which AiTiA LVSD scores increase as ventricular function deteriorates and decrease as function improves.

If validated prospectively for longitudinal use, this could extend AI-ECG beyond binary screening.

Serial ECGs might potentially provide a relatively low-burden digital signal suggesting deterioration or improvement in an underlying ventricular phenotype.

That possibility remains investigational.

It should not currently be interpreted as a replacement for serial echocardiography, clinical assessment, biomarkers, or other established methods of monitoring patients with heart failure.

But the concept is important.

It raises the possibility that the ECG-derived AI score may ultimately function not only as a screening output but as a quantitative digital biomarker whose trajectory contains clinically relevant information.

That hypothesis deserves prospective evaluation.

External Validation and Generalizability Are Critical

High model performance in a development or pivotal cohort does not guarantee equivalent performance across clinical environments.

AI-ECG models can potentially be influenced by differences in:

Patient demographics.

Disease prevalence.

Comorbidity burden.

Referral patterns.

ECG hardware.

Sampling characteristics.

Signal preprocessing.

Clinical setting.

Healthcare-system population.

Disease spectrum.

Threshold selection.

These are not theoretical concerns.

They are fundamental questions for any diagnostic AI technology.

A model intended for broad clinical use should therefore demonstrate that performance remains clinically acceptable outside the population in which it was originally developed.

Medical AI's materials describe international collaborations and external evaluation across multiple institutions and populations.

Continued independent external validation will be particularly important as the technology enters additional healthcare systems and as new indications are developed.

For cardiologists, the question is not simply whether an algorithm works.

It is:

Does it work in my patients, in my clinical environment, at the threshold and prevalence relevant to the decision I am trying to make?

Clinical Utility Must Ultimately Extend Beyond Diagnostic Accuracy

Even excellent diagnostic performance does not automatically establish clinical utility.

A model can discriminate effectively between patients with and without a phenotype while still failing to improve care if its output does not change clinical decisions appropriately.

The critical downstream questions include:

Does AI-ECG identify disease earlier?

Does it appropriately increase confirmatory testing among patients most likely to benefit?

Does it avoid excessive unnecessary imaging?

Does earlier identification result in earlier guideline-directed therapy?

Does it improve referral efficiency?

Does it meaningfully change patient outcomes?

Does it create additional workflow burden?

What is the false-positive burden at scale?

How should clinicians respond to discordance between the AI result and the conventional ECG, symptoms, biomarkers, or prior imaging?

These questions move the discussion from algorithmic performance to clinical utility.

That is where the ultimate value of AI-ECG will be determined.

Workflow Integration Is Part of the Clinical Intervention

Medical AI's proposed implementation integrates AI analysis with the existing ECG and hospital-information workflow.

In its technical materials, the AI-ECG order is entered through the hospital information system, the ECG is acquired, and the resulting AI score and interpretation are incorporated into the existing ECG report.

This matters.

Physicians do not need another isolated portal generating another stream of alerts.

The AI output should appear where clinicians already interpret cardiovascular information and should connect to a defined clinical response.

A positive result must answer the practical question:

What should I do next?

Depending on the indication, patient population, regulatory labeling, and clinical circumstances, that could include:

Review of symptoms and examination findings
Comparison with previous ECGs
Natriuretic peptide testing
Echocardiography
Review of prior cardiac imaging
Cardiology referral
Additional disease-specific evaluation

AI without an actionable pathway risks becoming another data element.

AI embedded into an evidence-based clinical workflow has the potential to become decision support.

Opportunistic Screening May Be One of the Most Important Applications

ECGs are already acquired across a wide range of clinical environments:

Primary care
Emergency medicine
Preoperative evaluation
Cardiology
Oncology
Chronic disease management
Hospital admission
Routine health evaluation

Many patients undergo ECGs for reasons unrelated to screening for LV systolic dysfunction.

If an appropriately validated and authorized algorithm can extract another clinically meaningful signal from the same digital recording, an ECG already being performed becomes an additional opportunity for disease detection.

This is the concept of opportunistic screening.

Instead of asking:

"Should we perform another screening procedure on every patient?"

AI allows us to ask:

"What additional validated clinical information can be extracted from physiologic data we are already collecting?"

For healthcare systems performing large volumes of ECGs, that distinction could become significant.

AI Does Not Need to Replace the Cardiologist to Transform the ECG

The relevant benchmark is not whether artificial intelligence can replace a cardiologist.

It should not.

The more meaningful question is whether AI can extract reproducible information from physiologic data that helps physicians:

recognize disease earlier,

identify patients for definitive testing more effectively,

quantify previously inaccessible risk signals,

identify clinically relevant phenotypes that conventional ECG interpretation may not reveal.

AI-ECG is particularly compelling because it applies that concept to one of the oldest, fastest, and most ubiquitous diagnostic tests in cardiovascular medicine.

The traditional ECG converts cardiac electrical activity into a waveform physicians can interpret.

AI introduces an additional analytical layer.

It interrogates the underlying digital signal at a dimensionality that human visual interpretation cannot practically reproduce.

The result is not a replacement for physician judgment.

It is potentially a new class of digital biomarker derived from a familiar physiologic test.

The Future of the 10-Second ECG

The same 10-second recording can continue to provide the rhythm, conduction, ischemic, and other information clinicians have relied upon for generations.

But the underlying raw signal may contain substantially more clinically relevant information than conventional interpretation has historically been able to extract.

Deep learning provides a mechanism for interrogating that information.

The scientific literature has already demonstrated that AI-ECG can identify electrical signatures associated with reduced ventricular function, while the broader field is investigating additional structural, functional, ischemic, electrophysiologic, and systemic phenotypes.

Medical AI's long-term strategy is to expand AiTiA into a multi-indication AI-ECG platform.

If additional algorithms demonstrate rigorous clinical validity and successfully complete the applicable regulatory pathways, the result could be a highly sophisticated form of cardiovascular decision support built on one of medicine's simplest and most familiar physiologic tests.

The elegance of the model is the contrast:

A 10-second acquisition.
A familiar 12-lead ECG.
Tens of thousands of numerical measurements.
Potentially multiple independently validated clinical inferences.

But physicians should demand the same standards from AI that they demand from every other medical technology:

Rigorous evidence.

Independent external validation.

Appropriate regulatory review.

Generalizability.

Calibration.

Clearly defined intended use.

Demonstrated clinical utility.

And ultimately, meaningful benefit to patient care.

The question should never be whether an algorithm is impressive because it uses artificial intelligence.

The appropriate question is:

Does it provide validated, reproducible, clinically actionable information that improves what we can learn from the ECG and helps us make better decisions for the patient?

If AI-ECG can continue answering that question affirmatively across multiple indications, the 12-lead ECG may evolve from one of cardiovascular medicine's oldest diagnostic technologies into one of its most analytically sophisticated.

About Medical AI and CG Moneta Consulting

Medical AI develops artificial intelligence software designed to analyze raw electrocardiographic signals for cardiovascular and other clinically relevant phenotypes. Its AiTiA platform applies deep learning to routine digital ECG data with the objective of identifying disease-associated signal patterns that may not be apparent through conventional electrocardiographic interpretation alone.

CG Moneta Consulting is working with Medical AI to support evaluation of AI-ECG technology within U.S. healthcare organizations, including participation in the AiTiA LVSD Silent Mode Study.

AiTiA LVSD is currently undergoing U.S. regulatory evaluation and is not currently authorized for commercial clinical use in the United States. During the Silent Mode Study, AI-generated results are not provided to participating clinicians for clinical decision-making.

Selected References

Medical AI Co., Ltd. AI-ECG for Early Detection of Cardiac Diseases / AiTiA LVSD. Technical and clinical presentation.

Attia ZI, et al. Screening for cardiac contractile dysfunction using an artificial intelligence-enabled electrocardiogram. Nature Medicine. 2019.

Yao X, et al. Artificial intelligence-enabled electrocardiograms for identification of patients with low ejection fraction: a pragmatic, randomized clinical trial. Nature Medicine. 2021.

U.S. Food and Drug Administration. Artificial Intelligence-Enabled Medical Devices.

You Can’t Fix What You Can’t See: Why Revenue Cycle Visibility Matters

Sun, 13 Sep 2026 20:35:03 GMT

Healthcare providers track more revenue cycle data than ever before. The greater challenge is determining whether that data provides a complete picture of where revenue is being lost—and why.

You Can’t Fix What You Can’t See: Why Revenue Cycle Visibility Matters

Healthcare providers track more revenue cycle data than ever before. The greater challenge is determining whether that data provides a complete picture of where revenue is being lost—and why.

Healthcare organizations monitor an extraordinary amount of financial and operational data.

Days in A/R. Denial rates. Clean claim rates. Cash collections. Discharged-not-final-billed accounts. Coding productivity. Bad debt. Payer performance. Authorization rates.

Each metric provides valuable information.

But there is a more fundamental question healthcare leaders should be asking:

Do these metrics provide visibility into the entire revenue cycle—or are they showing individual pieces of a much larger financial picture?

Revenue leakage does not necessarily result from one major breakdown.

It can occur incrementally across processes, systems, departments, payers, and workflows.

A missed charge.

A coding variance.

An authorization issue that later becomes a denial.

A claim that remains unresolved longer than necessary.

A payer reimbursement that does not align with expectations.

A denied claim that is not successfully appealed.

An aging account that receives insufficient follow-up.

Individually, these issues may appear manageable.

Across a large volume of patient encounters and claims, however, recurring inefficiencies can create meaningful financial exposure.

And unless leadership can see how these issues connect across the entire revenue cycle, an organization may be addressing symptoms without identifying the underlying causes.

Revenue Leakage Doesn't Begin With the Denial

When a claim is denied, the financial problem becomes visible.

But the issue that contributed to the denial may have occurred days, weeks, or even months earlier.

The healthcare revenue cycle begins well before a claim reaches a payer.

Patient registration, insurance eligibility, prior authorization, clinical documentation, charge capture, coding, claim creation, clearinghouse processing, payer adjudication, payment posting, denial management, collections, and follow-up are interconnected.

The Healthcare Financial Management Association defines revenue cycle management as encompassing the activities that lead to payment for healthcare services, beginning with the patient's initial encounter and continuing through final payment.

That means a problem at one stage can create financial consequences somewhere else.

Incomplete documentation can affect coding.

Coding can affect claim accuracy.

Registration or authorization issues can contribute to denials.

Delayed charge entry can delay billing.

Payer reimbursement variance can reduce expected collections.

Weak follow-up can allow otherwise recoverable revenue to age.

The denial, underpayment, or aging receivable may therefore be the financial outcome of an issue that originated much earlier in the revenue cycle.

That is why evaluating isolated metrics may not always reveal the complete story.

Reporting Is Not the Same as Visibility

Most healthcare organizations have revenue cycle reporting.

That does not necessarily mean leadership has complete visibility into the causes of financial performance.

A dashboard may tell leadership what happened.

A deeper forensic review should help determine why it happened, where it originated, what financial exposure may exist, and whether the issue appears isolated or systemic.

Consider an organization with an elevated denial rate.

Knowing the rate is important.

But it immediately creates additional questions.

Which payers are driving the denials?

Which service lines are affected?

Are problems originating in registration, eligibility, authorization, documentation, coding, claim submission, or payer adjudication?

Are particular denial categories increasing?

Are the same problems recurring?

How quickly are denied claims being worked?

How many are successfully overturned?

How much expected reimbursement is ultimately written off?

Are workflow, staffing, or technology limitations contributing to the problem?

And perhaps most importantly:

Is the denial rate itself the problem—or is it evidence of problems occurring somewhere else in the revenue cycle?

That distinction moves the conversation from simply measuring performance to understanding it.

Small Problems Become Large Numbers at Scale

Healthcare revenue cycles operate at significant scale.

That makes relatively small recurring inefficiencies financially important.

For a healthcare organization generating $500 million in annual net patient revenue, 1% represents $5 million.

For an organization generating $1 billion, 1% represents $10 million.

Those examples are not intended to suggest that every provider is losing 1% of revenue.

They simply demonstrate the effect of scale.

A process does not have to be dramatically broken to create a material financial impact.

A small, recurring problem multiplied across a large revenue cycle can become a significant number.

This is one reason executive visibility matters.

Leadership cannot properly prioritize an issue until it understands both its operational cause and its financial significance.

The Revenue Cycle Is Too Interconnected to Evaluate Only in Silos

Healthcare organizations naturally divide revenue cycle responsibilities among specialized teams.

Patient access may manage registration and eligibility.

Clinical departments are responsible for documentation.

Coding teams translate clinical activity into billable information.

Billing teams submit claims.

Denial teams work rejected or denied claims.

Collections teams manage receivables.

Contracting teams negotiate payer agreements.

Finance monitors the resulting performance.

Operationally, this specialization makes sense.

Financially, however, the revenue cycle remains one interconnected system.

When each function is evaluated primarily through its own metrics, relationships between problems can be difficult to identify.

A documentation issue may appear later as a coding problem.

A coding problem may become a claim edit.

A claim edit may create a submission delay.

A submission delay may contribute to aging A/R.

An authorization issue may appear weeks later as a denial.

A reimbursement variance may initially appear to be a collection issue when the underlying problem relates to payer adjudication or contract interpretation.

The point at which financial performance deteriorates is not always the point at which the underlying problem began.

That is precisely why an enterprise-wide perspective matters.

Denials Are Only One Part of the Financial Picture

Denials understandably receive significant attention because they are visible.

A payer explicitly declines or reduces payment.

But revenue can also be affected without a formal denial.

A claim can be paid but reimbursed differently than expected.

A service can be delivered without being completely captured.

Documentation can fail to support the appropriate coding.

A claim can be submitted later than necessary.

An account can remain unresolved until collection becomes increasingly difficult.

A workflow can require substantial manual rework, increasing the administrative cost of collecting the revenue.

Patterns of payer behavior can also persist without becoming apparent when claims are reviewed individually rather than across a broader population.

These issues may not appear neatly on a denial dashboard.

That is why revenue integrity requires a broader perspective than denial management alone.

Why an Independent Forensic Review Can Matter

Healthcare organizations routinely evaluate performance across clinical, compliance, financial, operational, and technology functions.

Revenue-cycle performance deserves similarly rigorous scrutiny.

A forensic RCM audit should not simply be an exercise in locating individual unpaid claims.

Its greater value is establishing an objective baseline of how the revenue cycle is actually performing and identifying where deeper investigation or intervention may be warranted.

Depending on the organization and the scope of review, that analysis may include:

Documentation integrity and completeness
Charge capture
Coding accuracy and variance
Claim creation and submission
Clearinghouse activity and unresolved edits
Denial patterns and root causes
Payer reimbursement variance
Potential underpayments
Aging accounts receivable
Collections and follow-up
Workflow bottlenecks
Operational handoffs
Reporting gaps
Revenue integrity exposure

The objective should not be to assume something is wrong.

It should be to validate what is working, identify what is not, quantify material areas of exposure where possible, and determine where corrective action would have the greatest impact.

That distinction is important.

A credible audit should not begin with a predetermined solution.

It should begin with questions.

Establish the Baseline Before Prescribing the Solution

Healthcare organizations are continually presented with RCM technologies, outsourcing models, AI platforms, consulting engagements, workflow solutions, and operating models promising better performance.

Many can provide genuine value.

But implementing a solution before clearly identifying the problem creates its own risk.

If leadership has not established where financial performance is deteriorating and why, how can it know which intervention deserves priority?

A coding issue requires one response.

An authorization issue requires another.

A payer reimbursement issue may require another.

A staffing, workflow, or technology constraint may call for something entirely different.

The first question therefore should not necessarily be:

"What solution should we implement?"

It should be:

"What is actually happening across our revenue cycle?"

Once that baseline exists, leadership can make more informed decisions regarding remediation, technology, staffing, outsourcing, payer escalation, workflow redesign, or broader revenue-cycle transformation.

An Audit Should Produce an Executive Roadmap

The output of a meaningful RCM audit should not simply be a lengthy list of observations.

It should translate operational findings into financial and strategic priorities.

Leadership should be able to answer several fundamental questions.

What is happening?

Where is reimbursement or operational performance deteriorating?

Why is it happening?

What documentation, coding, payer, workflow, claims, collection, or operational issues are contributing?

What is the financial significance?

Which identified issues appear to create the greatest exposure or opportunity?

What should be addressed first?

Which problems are most urgent, recoverable, or likely to produce meaningful improvement?

What should happen next?

Can the issue be addressed internally, does it require targeted outside expertise, or does a broader portion of the revenue cycle require intervention?

That is when an audit becomes more than a retrospective review.

It becomes an executive decision-making tool.

Sometimes the Audit May Validate the Existing Operation

There is another potential benefit of independent review that receives far less attention.

An audit does not have to uncover a major failure to create value.

It may demonstrate that an internal revenue cycle team is performing effectively.

It may validate that an existing RCM partner is delivering strong results.

It may show that certain functions should remain exactly as they are while identifying only targeted opportunities for improvement.

Those are valuable outcomes.

The purpose of an objective audit should not be to manufacture problems.

It should be to give leadership confidence that it understands the actual performance of the revenue cycle.

Sometimes that means identifying material financial exposure.

Sometimes it means finding a limited number of correctable issues.

And sometimes it means confirming that existing processes are working as intended.

In each case, leadership gains something important:

better information on which to base decisions.

The Cost of Not Knowing

Revenue-cycle leakage is particularly difficult to manage when leadership cannot see where it is occurring or quantify its significance.

If an organization identifies a defined area of financial exposure, leadership can evaluate the cause, prioritize it, and decide whether intervention is justified.

The more difficult position is not knowing the magnitude of the exposure—or which processes are creating it.

That is the real value of stronger revenue-cycle optics.

It transforms uncertainty into information.

Information into priorities.

And priorities into action.

Revenue Integrity Begins With Visibility

Healthcare providers operate in an increasingly complex financial environment.

Payer requirements, reimbursement complexity, staffing pressures, administrative costs, regulatory requirements, and changing technology all affect revenue-cycle performance.

There will always be another dashboard, another KPI, and another technology promising to improve performance.

Before adding another solution, however, healthcare leaders should answer a more fundamental question:

Do we truly understand what is happening across our entire revenue cycle?

This is the philosophy behind the Elevate Medical Revenue Cycle Forensic Audit offered through CG Moneta Consulting.

Elevate begins with a forensic review of reimbursement performance, denial exposure, payer behavior, coding variance, unresolved receivables, documentation, workflows, and other areas affecting revenue-cycle performance.

The purpose of the audit is not to begin with a predetermined operating solution.

It is to establish the facts first.

Identify root causes.

Assess financial exposure.

Prioritize opportunities.

And then determine what—if anything—should change.

Because before a healthcare organization can optimize its revenue cycle, leadership first needs the visibility to understand it.

Revenue integrity begins with knowing where performance is breaking down—and why.

Sources

Healthcare Financial Management Association (HFMA). Healthcare Revenue Cycle Management (RCM) — What It Is & How It Works. Overview of revenue-cycle activities from the initial patient encounter through final payment.

Healthcare Financial Management Association (HFMA). Standardizing Denial Metrics for Revenue Cycle Benchmarking and Process Improvement. Guidance addressing denial measurement, denial write-offs, appeal timing, benchmarking, and revenue-cycle performance.

CG Moneta Consulting. Elevate Medical Revenue Cycle Forensic Audit. Overview of the Elevate methodology for evaluating reimbursement performance, denial exposure, payer behavior, coding variance, unresolved receivables, operational constraints, and remediation priorities.

The Missing Link in Healthcare: Why a Complete Patient Medical Record Matters

Sun, 13 Sep 2026 20:28:09 GMT

Why fragmented health information continues to burden patients—and how a longitudinal medical record can give providers a more complete view of the patient.

Why Are Patients Still Responsible for Bringing Their Medical Records with Them?

Healthcare has never generated or stored more patient information.

Yet a patient can walk into a new physician’s office and still hear a familiar request:

“Can you contact your other providers and have them send us your medical records?”

For patients who receive most of their care within a single health system, this problem may be less noticeable. But healthcare rarely operates within such clean boundaries.

A patient may see a primary care physician affiliated with one health system, a cardiologist in another, an independent orthopedic specialist, an imaging center, a laboratory, an urgent care facility, and perhaps a hospital while traveling.

Every encounter adds another piece to the patient’s medical history.

The patient is one person. Their medical history may be scattered across numerous organizations and systems.

Despite tremendous advances in electronic health records and healthcare interoperability, patients can still find themselves responsible for connecting those pieces.

When the Patient Becomes the Health Information Exchange

Anyone who has changed physicians, sought a second opinion, or received care outside their usual health system may recognize the process.

Which physicians have you seen? Where was your last MRI performed? What medications have you previously taken? When did you have that procedure? Can you get us a copy of the report? Can you ask your previous physician to send us the records?

The patient may then have to remember which organization has the information, locate the appropriate portal or medical records department, submit a request, obtain the records, and make sure the information reaches the new provider.

Federal data demonstrates that this remains a real problem.

According to the Office of the National Coordinator for Health Information Technology (ONC), 21% of individuals who visited a healthcare provider reported in 2022 that they had to bring a prior test result, such as an X-ray or MRI, to an appointment. In 2024, 10% reported having to redo a test or procedure because the earlier results were unavailable.

ONC describes these findings as evidence of persistent gaps in the information needed to inform patient care and follow-up.

Now consider experiencing this process while managing cancer, cardiovascular disease, diabetes, multiple chronic conditions, or the healthcare needs of an aging parent.

The inconvenience can quickly become a significant burden.

Patients Should Know Their History. They Shouldn’t Have to Reconstruct It.

Patients should be active participants in their healthcare. Access to their medical information is an important part of that participation.

Under HIPAA, individuals generally have the right to access a broad range of protected health information contained in designated record sets maintained by covered healthcare providers and health plans, subject to limited exceptions.

But there is an important distinction between giving patients access to their medical information and making patients responsible for assembling a clinically meaningful medical history from multiple healthcare organizations.

Patients cannot reasonably be expected to remember every laboratory result, medication change, imaging finding, procedure, diagnosis, specialist recommendation, hospitalization, or previous treatment decision that could become important during a future episode of care.

They also may not know which parts of that history could be clinically relevant to the provider treating them today.

A patient can explain what they remember.

A longitudinal medical record can provide a broader view of what actually occurred.

The Information Exists. The Challenge Is Bringing It Together.

Healthcare has made enormous progress in digitizing and exchanging medical information.

Electronic health records, health information exchanges, standardized APIs, information-blocking requirements, and nationwide interoperability initiatives are making more health information electronically accessible.

The federal Trusted Exchange Framework and Common Agreement, or TEFCA, is designed specifically to advance nationwide health information exchange across organizational and technology boundaries.

That progress is significant.

But making information electronically exchangeable and turning information from multiple sources into a comprehensive, clinically useful longitudinal history are not necessarily the same thing.

A patient’s information may exist across hospitals, physician practices, specialists, laboratories, pharmacies, imaging facilities, payers, health information exchanges, and other sources.

A provider’s EHR may contain an excellent record of what occurred within that organization without necessarily providing a complete picture of what occurred throughout the patient’s healthcare journey.

That distinction matters.

What Could Be Missing From the Picture?

Consider a physician seeing a new patient.

The information immediately available may include current diagnoses, medications, laboratory results, and recent encounters.

But elsewhere there could be relevant imaging, previous medication trials, specialist evaluations, hospitalizations, procedures, allergies or intolerances, laboratory trends, or other clinical history.

No single missing record automatically changes a clinical decision.

But collectively, fragmented information can leave providers without potentially relevant context that exists elsewhere.

Fragmentation can also create additional administrative work.

Clinical staff may spend time contacting other providers, requesting records, monitoring incoming documents, searching external systems, and reviewing large volumes of information simply to reconstruct a patient’s history.

And, as ONC’s national data demonstrates, some patients continue to report repeating tests or procedures because previous results were unavailable.

The fundamental problem is not always that the information does not exist.

It is whether relevant information can be brought together and made useful when the provider needs it.

What If the Medical History Followed the Patient?

Instead of expecting every provider—or every patient—to reconstruct the medical record independently, consider a different model.

Relevant records are retrieved from sources across the healthcare ecosystem.

The information is reconciled and organized.

Duplicate information is addressed.

The clinically meaningful history is summarized.

The underlying information remains traceable to its sources.

And the resulting longitudinal history is delivered into the provider’s existing workflow.

The objective is not simply to obtain more data.

The objective is to turn fragmented healthcare information into a usable picture of the patient.

That capability exists today.

How MedSync Is Addressing the Problem

CG Moneta Consulting has partnered with MedSync to bring its medical-record aggregation and clinical review capabilities to healthcare providers.

MedSync retrieves patient information from more than 2,500 data sources nationwide, including EHRs, health information exchanges, hospitals, laboratories, imaging centers, pharmacies, payers, specialists, and other sources.

But retrieving records is only the beginning.

MedSync’s process includes several important steps:

Retrieve: Records are gathered from available sources across the healthcare ecosystem.
Reconcile: Information is normalized, de-duplicated, identity-matched, and placed on a timeline.
Summarize: MedSync’s clinical team develops an H&P-style RECAP — Reviewed Evidence Comprehensive Assessment Profile.
Quality Check: The RECAP undergoes a multi-step quality process with clinical oversight.
Deliver: The completed RECAP is delivered into the healthcare organization’s preferred destination and existing workflow.

Instead of simply providing another collection of records for a physician or clinical team to sort through, RECAP is designed to consolidate information into a comprehensive patient history that can be efficiently reviewed.

For patients with multiple conditions, providers, and healthcare touchpoints, the goal is to provide greater clarity before decisions are made.

From Medical Record Retrieval to Clinically Useful Information

This distinction is important.

Healthcare organizations do not necessarily need another repository containing hundreds or thousands of pages of medical records.

They need information that can be used.

MedSync’s model addresses both sides of that challenge: finding the available information and making it more clinically useful.

Records from multiple sources are consolidated into a longitudinal history rather than remaining isolated within the organizations that generated them.

The resulting RECAP is then delivered where the healthcare team already works, reducing the need to introduce another disconnected portal into the clinical workflow.

For healthcare providers, this creates an opportunity to approach medical-record retrieval differently.

Instead of asking:

“Where are the patient’s records?”

the more important question becomes:

“Do we have the relevant information necessary to understand this patient’s healthcare journey?”

A Foundation for More Connected Care

Medical-record aggregation can also provide a foundation for broader care coordination.

When a healthcare organization has greater visibility into a patient’s history across multiple providers and care settings, its clinical team may be better positioned to identify information requiring additional review and coordinate appropriate follow-up.

The longitudinal record therefore does not have to represent the end of the process.

It can become the foundation for a more connected approach to understanding and coordinating the patient’s care.

This is particularly relevant for complex and high-risk patients whose healthcare journeys may involve numerous physicians, specialists, facilities, medications, procedures, and transitions of care.

The more complicated the healthcare journey becomes, the more valuable it can be to see that journey as one connected history rather than a collection of isolated encounters.

Patients Shouldn’t Have to Carry the Healthcare System on Their Shoulders

Patients should have access to their medical information.

They should understand their health, participate in decisions, and have the ability to share their information with the people and organizations involved in their care.

But that is very different from requiring patients to function as the primary mechanism for transferring their medical history from one healthcare organization to another.

Healthcare interoperability continues to advance. TEFCA and other initiatives are creating infrastructure intended to allow health information to move more securely and effectively across organizational boundaries.

The next challenge is ensuring that available information becomes accessible, consolidated, clinically useful, and integrated into the workflows where healthcare decisions are actually made.

Healthcare organizations can increasingly move away from asking:

“Can the patient get us those records?”

and toward asking:

“How can we make sure our providers have the relevant patient history when they need it?”

That represents a fundamentally different way of thinking about health information—one centered not on the organization where the data happens to reside, but on the patient whose healthcare journey that data represents.

The Patient Is One Person. Their Medical History Should Tell One Story.

A patient’s healthcare journey may cross multiple physicians, specialists, hospitals, laboratories, pharmacies, imaging centers, and health systems.

Their medical history should not have to start over each time it does.

At CG Moneta Consulting, we believe healthcare innovation should reduce friction for healthcare providers and the patients they serve. Our partnership with MedSync provides healthcare organizations with an opportunity to bring fragmented patient information together, make it more clinically useful, and deliver it into the workflows where care decisions are made.

The patient is one person. Their medical history should tell one connected story.

Learn More

CG Moneta Consulting is working with healthcare organizations interested in evaluating MedSync’s medical-record aggregation and RECAP capabilities.

To learn more or discuss how MedSync could support your organization, contact CG Moneta Consulting.

Sources

Office of the National Coordinator for Health Information Technology (ONC). Gaps in Individuals’ Information Exchange. Health IT Quick Stat #56. ONC reports persistent information-exchange gaps, including patients bringing prior test results to appointments and repeating tests or procedures when previous results were unavailable.

Office of the National Coordinator for Health Information Technology (ONC). Trusted Exchange Framework and Common Agreement (TEFCA). Information regarding the federal framework supporting secure nationwide electronic health information exchange.

U.S. Department of Health and Human Services (HHS), Office for Civil Rights. Individuals’ Right under HIPAA to Access their Health Information. Guidance regarding individuals’ rights to access protected health information contained in designated record sets.

MedSync Corp. RECAP — Reviewed Evidence Comprehensive Assessment Profile. Information regarding MedSync’s medical-record retrieval, reconciliation, summarization, quality-review, and delivery process.

The High Cost of Inaction: Why Ignoring Cost Reduction Audits and Tax Incentives Could Be Your Biggest Financial Mistake

Wed, 04 Sep 2024 16:39:54 GMT

In the fast world of business, it's easy to get caught up in the day-to-day operations and overlook opportunities for financial optimization.

In the fast-paced world of business, where every dollar counts, it’s easy to get caught up in day-to-day operations and overlook opportunities for financial optimization. However, neglecting to conduct regular cost reduction audits or explore available tax incentives can have significant, long-term consequences for your business. These oversight areas, often seen as non-urgent, can lead to substantial financial leakage and missed opportunities that could otherwise enhance your company’s profitability and sustainability.

The Hidden Dangers of Not Running a Cost Reduction Audit

Overpaying for Services and Supplies
Without a cost reduction audit, businesses are likely paying more than necessary for services and supplies. Over time, these excess costs can add up, eroding profit margins and reducing the financial flexibility needed for growth or unexpected expenses. A comprehensive audit can identify these areas of overspending and offer alternative solutions that maintain quality while cutting costs.
Inefficiency in Operations
Operational inefficiencies are often overlooked, especially when things seem to be running smoothly on the surface. However, inefficiencies can lead to wasted resources, both in terms of time and money. By not conducting regular audits, these inefficiencies remain unchecked, hindering your company’s ability to operate at its full potential. An audit can pinpoint these problem areas and suggest strategies for streamlining operations, ultimately boosting productivity and profitability.
Missed Opportunities for Competitive Advantage
Companies that regularly perform cost reduction audits are often more agile and competitive, as they have the financial resources to invest in innovation, marketing, and other growth initiatives. Without these audits, your business may struggle to keep up with competitors who have optimized their costs, putting you at a disadvantage in the marketplace.
Limited Cash Flow
Cash flow is the lifeblood of any business. Unnecessary expenses and inefficiencies can severely limit available cash flow, making it difficult to reinvest in the business, cover unexpected costs, or take advantage of new opportunities. A cost reduction audit can free up cash flow, providing the financial stability and flexibility needed to navigate the ups and downs of the business landscape.

The Risks of Ignoring Tax Incentives

Leaving Money on the Table
The tax code is filled with incentives designed to help businesses reduce their tax burden, but many companies fail to take advantage of these opportunities simply because they are unaware of them or don’t take the time to investigate. This is essentially leaving money on the table, money that could be reinvested in the business or used to improve financial stability.
Increased Tax Liability
Without a proactive approach to identifying and applying for tax incentives, businesses may end up with a higher tax liability than necessary. This not only reduces profitability but can also strain cash flow, particularly during times of economic uncertainty. Regularly reviewing available tax incentives ensures that your business is taking full advantage of the financial relief available, thereby minimizing tax liabilities.
Missed Opportunities for Growth and Expansion
Tax incentives can provide the financial boost needed to fund growth initiatives, such as expanding operations, hiring additional staff, or investing in new technology. By ignoring these incentives, businesses may miss out on opportunities for growth and expansion, ultimately limiting their long-term potential.
Overlooking Specialized Tax Incentives
Many businesses rely on their CPA firms for tax planning and compliance. Still, in many instances, these firms do not offer specialized tax incentives that could significantly reduce your tax burden. This is where a firm like CG Moneta Consulting comes in. By engaging a specialized tax incentive firm to calculate and identify these incentives, you can ensure that you’re capturing every available benefit. Your CPA can then consult on how best to utilize these incentives, ensuring seamless integration into your broader tax strategy.
Non-Compliance Risks
The tax landscape is complex and constantly changing. By not staying on top of available incentives and ensuring that your business is compliant with the latest tax laws, you risk facing penalties, fines, and even legal action. A thorough review of tax incentives, coupled with expert advice, can help mitigate these risks and ensure that your business remains compliant while maximizing financial benefits.

The consequences of not running a cost reduction audit or reviewing available tax incentives are clear: higher costs, inefficiencies, missed growth opportunities, and increased tax liabilities. In today’s competitive business environment, where every dollar matters, overlooking these critical areas can be a costly mistake.

By taking a proactive approach to cost reduction and tax planning, you can unlock significant financial benefits that will not only improve your bottom line but also provide the financial flexibility needed to thrive in the long term. Don’t let inaction undermine your business’s potential—invest in regular audits and tax incentive reviews to ensure your company is operating as efficiently and profitably as possible.

Uncovering Hidden Opportunities: The Importance of Medical Billing and Coding Forensic Audits

Sat, 03 Aug 2024 11:11:18 GMT

The Revenue Cycle: The Lifeblood of Your Practice

In the ever-evolving landscape of healthcare, medical practices face the constant challenge of maintaining financial health while delivering high-quality patient care. One of the most effective strategies to address this challenge is conducting a forensic audit of your medical billing and coding processes. This deep dive into your revenue cycle can unveil hidden opportunities to enhance revenue and streamline operations.

The Revenue Cycle: The Lifeblood of Your Practice

The revenue cycle in a medical practice encompasses every step from patient registration to the final payment of a balance. Each phase is critical, and any inefficiency or error can significantly impact the practice's financial health. Billing and coding are at the heart of this cycle, translating clinical services into billable charges.

Why Conduct a Medical Billing and Coding Forensic Audit?

Identify Revenue Leakage:

Revenue leakage occurs when potential income is lost due to errors in billing and coding. These errors can be as simple as incorrect patient information or as complex as improper coding for services rendered. A forensic audit meticulously examines these aspects to identify and rectify issues, ensuring that no revenue is left on the table.

Enhance Compliance:

Compliance with healthcare regulations is paramount. Inaccurate coding or billing practices can lead to significant penalties and legal issues. A forensic audit helps ensure that your practice adheres to the latest regulations, mitigating the risk of audits from external bodies and potential fines.

Optimize Reimbursement Rates:

Accurate and efficient coding directly impacts reimbursement rates from insurance providers. By identifying and correcting coding errors, a forensic audit can help optimize these rates, ensuring that your practice receives the maximum allowable reimbursement for services provided.

Improve Operational Efficiency:

Billing and coding inefficiencies can lead to delayed payments and increased administrative burdens. An audit not only identifies these inefficiencies but also provides actionable recommendations to streamline processes. This can result in faster payment cycles and reduced workload for your administrative staff.

The Process of a Forensic Audit

At CG Moneta Consulting and Elevate Medical Resources, we specialize in conducting comprehensive forensic audits tailored to your practice's unique needs. Our combined expertise of over 90 years in financial services, billing, and coding allows us to deliver unparalleled insights and strategies.

Data Collection and Analysis:

We begin with a thorough review of your billing and coding data from the past six months. This data-driven approach ensures a detailed understanding of your current practices.

Identifying Discrepancies and Inefficiencies:

Our team meticulously examines the data to identify discrepancies, errors, and inefficiencies. We focus on uncovering patterns that may indicate underlying issues affecting your revenue cycle.

Providing Actionable Insights:

Upon completing the audit, we present our findings along with actionable recommendations. These insights are designed to enhance revenue, improve compliance, and streamline operations.

Implementing Changes:

The final step is the implementation of recommended changes. We work closely with your team to ensure a smooth transition, providing support and guidance throughout the process.

The Benefits of Partnering with Experts

Conducting a forensic audit is a complex and time-consuming task that requires specialized knowledge and expertise. Partnering with experts like CG Moneta Consulting and Elevate Medical Resources ensures that the audit is thorough and accurate, providing you with a clear path to improved financial health and operational efficiency.

In today's competitive healthcare environment, maintaining a healthy revenue cycle is crucial for the sustainability and growth of your practice. A forensic audit of your billing and coding processes is an invaluable tool to uncover hidden opportunities, enhance revenue, and streamline operations. By investing in this comprehensive review, you can ensure that your practice is well-positioned for long-term success.

Maximizing Revenue Recovery: The Case for Underpayment Audits for Healthcare Organizations

Thu, 21 Mar 2024 14:19:35 GMT

The consequences of underpayments are far-reaching and can have profound effects

In the ever-evolving landscape of healthcare finance, the efficient management of revenue streams is paramount to the sustainability and success of healthcare organizations. Among the myriad challenges faced by providers, underpayments from insurance payers stand out as a significant threat to financial stability. To combat this issue effectively, healthcare organizations must embrace underpayment audits as an essential tool for revenue recovery and financial health.

Understanding Underpayments in Healthcare

Underpayments occur when insurance payers reimburse healthcare providers at rates lower than what was contractually agreed upon or warranted for the services rendered. These discrepancies can stem from various sources, including coding errors, billing inaccuracies, contractual misinterpretations, and changes in reimbursement policies.

The consequences of underpayments are far-reaching and can have profound effects on the financial viability of healthcare organizations:

Revenue Loss : Underpayments directly impact the bottom line, resulting in decreased revenue and potentially limiting resources available for critical patient care services, infrastructure investments, and staff retention efforts.
Operational Strain : Healthcare providers must navigate complex reimbursement processes and devote valuable time and resources to reconciling underpayments, diverting attention from core clinical and administrative functions.
Contractual Risks : Persistent underpayments can erode trust and strain relationships with insurance payers, jeopardizing future contract negotiations and potentially leading to legal disputes or contract terminations.

The Role of Underpayments Audits

Underpayments forensic audits involve a meticulous examination of billing and reimbursement data to identify instances of underpayment, quantify their financial impact, and pursue appropriate remediation strategies. Key components of underpayments forensic audits may include:

Data Analysis : Auditors analyze vast datasets encompassing claims, remittance advices, contractual agreements, and fee schedules to pinpoint discrepancies and anomalies indicative of underpayment.
Contract Compliance Review : Auditors scrutinize payer contracts and reimbursement terms to ensure adherence and identify instances where payers have failed to meet their contractual obligations.
Root Cause Analysis : Auditors delve into the root causes of underpayments, uncovering underlying issues such as coding inaccuracies, claims processing errors, or payer policy changes that contribute to revenue leakage.
Recovery and Resolution : Upon identifying underpayments, auditors work collaboratively with healthcare organizations to initiate recovery efforts, appeal denials, negotiate with payers, and implement corrective measures to prevent future occurrences.

The Imperative for Underpayments Forensic Audits

The prevalence of underpayments in healthcare necessitates a proactive and systematic approach to revenue integrity management. Here's why every healthcare organization should prioritize underpayments forensic audits:

Maximizing Revenue Recovery : Underpayments forensic audits enable healthcare organizations to recoup lost revenue, thereby bolstering financial resources and strengthening financial resilience in an increasingly challenging healthcare environment.
Ensuring Contractual Compliance : By meticulously reviewing payer contracts and reimbursement terms, underpayments forensic audits ensure that insurance payers uphold their end of the bargain, safeguarding providers' financial interests and contractual rights.
Improving Operational Efficiency : Identifying and rectifying underpayments streamlines revenue cycle processes, reduces administrative burdens, and enhances operational efficiency, allowing healthcare organizations to focus on delivering high-quality patient care.
Mitigating Future Risks : Through root cause analysis and corrective action implementation, underpayments forensic audits help healthcare organizations address systemic issues contributing to underpayments, minimizing recurrence and mitigating future financial risks.

Underpayments forensic audits represent a proactive and strategic approach to revenue cycle management in healthcare. By conducting comprehensive analyses of billing and reimbursement data, healthcare organizations can identify, quantify, and remediate underpayments, thereby safeguarding financial health and optimizing revenue recovery efforts. As healthcare continues to evolve, underpayments forensic audits will remain indispensable tools for ensuring financial sustainability, operational efficiency, and the delivery of exceptional patient care. Embracing underpayments forensic audits is not merely an option but a necessity for healthcare organizations committed to thriving in an increasingly complex and competitive landscape.

Maximizing Value with CG Moneta Consulting: Your Partner in Telecom, Cloud, & IT RFPs

Sun, 17 Mar 2024 21:09:53 GMT

Our commitment to client satisfaction extends beyond the RFP process.

At CG Moneta Consulting, we pride ourselves on being leaders in creating, managing, and fulfilling Requests for Proposals (RFPs) in the domains of telecom, cloud, and IT services. Our commitment to excellence, coupled with our vendor-agnostic approach and extensive portfolio of over 300 best-in-class service providers, sets us apart as a trusted partner for companies of all sizes and industries. In this article, we'll delve into the unparalleled value that CG Moneta Consulting offers in optimizing procurement processes and significantly reducing costs for our clients.

Expertise in RFP Management

Crafting and managing RFPs can be a daunting task, especially in complex and rapidly evolving fields like telecom, cloud, and IT services. At CG Moneta Consulting, our team of seasoned experts brings years of experience and industry insights to the table. From defining project scopes and drafting comprehensive RFP documents to managing vendor communications and evaluating proposals, we handle every aspect of the RFP process with precision and professionalism.

Vendor-Agnostic Approach

Unlike traditional consulting firms aligned with specific service providers, CG Moneta Consulting remains vendor-agnostic, ensuring unbiased and objective recommendations tailored to our clients' unique needs. With a diverse portfolio comprising over 300 best-in-class service providers, we offer unparalleled flexibility and choice, enabling our clients to select solutions that best align with their business objectives, budgetary constraints, and performance requirements.

Cost Reduction at Procurement

One of the most significant advantages of partnering with CG Moneta Consulting is the ability to achieve substantial cost savings during procurement. By leveraging our extensive network of service providers and negotiating on behalf of our clients, we secure competitive pricing and favorable terms that often surpass what businesses could obtain independently. Our strategic approach to procurement ensures that our clients maximize value without compromising on quality or service excellence.

Tailored Solutions for Every Industry

Whether you operate in healthcare, finance, manufacturing, or any other industry, CG Moneta Consulting has the expertise and resources to meet your specific requirements. Our consultants possess in-depth knowledge of industry regulations, compliance standards, and technological trends, allowing us to design bespoke solutions that address your organization's unique challenges and opportunities.

Seamless Implementation and Ongoing Support

Our commitment to client satisfaction extends beyond the RFP process. At CG Moneta Consulting, we facilitate seamless implementation of chosen solutions and provide ongoing support to ensure optimal performance and ROI. From project management and vendor coordination to troubleshooting and performance monitoring, we remain dedicated to supporting our clients every step of the way.

In today's fast-paced business landscape, navigating the complexities of telecom, cloud, and IT procurement can be overwhelming. However, with CG Moneta Consulting as your trusted partner, you can unlock unparalleled value, streamline procurement processes, and achieve significant cost savings. Whether you're a small startup or a multinational corporation, our team is ready to empower your organization with tailored solutions and expert guidance. Reach out to CG Moneta Consulting today and experience the difference that expertise, innovation, and dedication can make in transforming your business.

Unveiling Specialized Tax Advantages: Empowering Businesses Across Industries

Sun, 17 Mar 2024 20:58:39 GMT

For SMEs, leveraging specialized tax advantages can be a game-changer

In the intricate world of business, maximizing profits while minimizing tax liabilities is a perpetual pursuit. Small and medium-sized enterprises (SMEs), the backbone of economies worldwide, often face the challenge of navigating through complex tax codes to optimize their financial resources. However, amidst this complexity lies a trove of specialized tax advantages tailor-made to empower businesses across industries. In this article, we delve into the realm of specialized tax incentives and their pivotal role in bolstering SMEs' growth and sustainability.

Understanding Specialized Tax Advantages

Specialized tax advantages encompass a diverse array of incentives and credits designed to stimulate specific sectors, promote innovation, and foster economic development. Unlike conventional tax deductions, these incentives offer targeted benefits to businesses, encouraging them to invest, expand, and thrive. From research and development (R&D) tax credits to energy-efficient deductions, these incentives cater to various industry needs, providing a competitive edge to businesses willing to seize the opportunity.

Importance for Small and Medium-Sized Businesses

For SMEs, leveraging specialized tax advantages can be a game-changer. These incentives serve as catalysts for growth, enabling businesses to allocate resources strategically, drive innovation, and enhance competitiveness. Moreover, they play a crucial role in leveling the playing field, empowering SMEs to compete with larger corporations on more equitable terms. By harnessing these incentives, SMEs can unlock hidden value within their operations, fueling expansion and long-term success.

Examples of Specialized Tax Advantages

Research and Development (R&D) Tax Credits: Aimed at fostering innovation, R&D tax credits incentivize businesses to invest in research and development activities. SMEs engaged in product development, process improvement, or technological advancements can claim substantial credits, offsetting a significant portion of their R&D expenditures.

Work Opportunity Tax Credit (WOTC): Designed to promote workforce diversity and inclusion, WOTC provides tax credits to businesses hiring individuals from targeted groups, including veterans, ex-felons, and long-term unemployed individuals. SMEs can harness this incentive to expand their talent pool while enjoying tax savings.

Energy-Efficient Tax Deductions: With a growing emphasis on sustainability, businesses investing in energy-efficient equipment and technologies can avail themselves of generous tax deductions. These incentives not only reduce operating costs but also contribute to environmental stewardship, enhancing businesses' corporate social responsibility.

Section 179 Deduction: SMEs investing in capital assets, such as equipment, machinery, and vehicles, can take advantage of the Section 179 deduction. This provision allows businesses to deduct the full purchase price of qualifying assets in the year of acquisition, providing immediate tax relief and encouraging investment.

The Role of Specialized Tax Consulting Firms

While specialized tax advantages offer immense potential, navigating through the complex tax landscape requires expertise and meticulous planning. Unlike traditional CPAs, who may lack the specialized knowledge and resources to identify and optimize these incentives, consulting firms like CG Moneta Consulting specialize in unlocking the full spectrum of tax-saving opportunities for SMEs. With a deep understanding of industry-specific incentives and regulatory nuances, these firms help businesses harness specialized tax advantages to their fullest potential, driving sustainable growth and profitability.

Specialized tax advantages represent a powerful tool for SMEs across industries, offering a pathway to enhanced competitiveness, innovation, and financial resilience. By embracing these incentives and partnering with expert consulting firms, businesses can embark on a journey of tax optimization, propelling them towards greater prosperity in an increasingly dynamic business environment.

Maximizing Profitability: The Significance of Specialized Tax Incentives for Small and Medium-Sized Businesses

Sun, 17 Mar 2024 20:49:05 GMT

SMBs operate in diverse industries, each with its own set of challenges and opportunities.

Small and medium-sized businesses (SMBs) are the backbone of economies worldwide, driving innovation, creating jobs, and fostering economic growth. However, these enterprises often face numerous challenges, with navigating complex tax regulations being one of the most daunting. To alleviate this burden and foster growth, specialized tax incentives tailored to SMBs across all industries play a crucial role. Unfortunately, many SMBs are unaware of these incentives, and even if they are, most CPAs lack the expertise to fully leverage them. This is where specialist firms like CG Moneta Consulting step in, providing invaluable assistance to SMBs seeking to optimize their tax strategies.

Understanding the Landscape

SMBs operate in diverse industries, each with its own set of challenges and opportunities. From manufacturing and technology to retail and hospitality, these businesses contribute significantly to the economy. However, the complexity of tax laws often overwhelms SMB owners, leading to missed opportunities for tax savings. Traditional CPAs, while proficient in general tax compliance, often lack the specialized knowledge required to identify and leverage industry-specific tax incentives.

The Role of Specialized Tax Incentives

Specialized tax incentives offer SMBs a pathway to reduce their tax burden and reinvest savings into their businesses. These incentives can take various forms, including tax credits, deductions, grants, and exemptions. They are designed to encourage specific behaviors or investments that stimulate economic growth, innovation, and job creation within targeted industries.

For example, in the technology sector, research and development (R&D) tax credits provide financial incentives for businesses that invest in innovation. Similarly, in the manufacturing industry, accelerated depreciation allowances can significantly reduce tax liabilities for investments in machinery and equipment. By tapping into these incentives, SMBs can enhance their competitiveness, fuel growth, and increase profitability.

The Gap in Expertise

Despite the potential benefits, many SMBs miss out on specialized tax incentives due to a lack of awareness and expertise. Traditional CPAs, while proficient in handling routine tax matters, often lack the specialized knowledge required to identify and maximize these incentives. As a result, SMBs may inadvertently overpay taxes and miss out on opportunities to reinvest in their businesses.

Bridging the Gap with Specialist Firms

Specialist firms like CG Moneta Consulting specialize in helping SMBs navigate complex tax landscapes and maximize their tax savings. With a team of experts versed in industry-specific tax incentives, these firms work closely with SMBs to uncover opportunities for tax optimization. By leveraging their in-depth knowledge and experience, specialist firms empower SMBs to take full advantage of available incentives, thereby enhancing their financial health and sustainability.

In conclusion, specialized tax incentives play a pivotal role in supporting the growth and success of SMBs across all industries. However, the complexity of tax regulations and the lack of expertise among traditional CPAs often hinder SMBs from fully capitalizing on these incentives. Specialist firms like CG Moneta Consulting bridge this gap by providing tailored solutions and expert guidance to help SMBs navigate the intricacies of tax law and maximize their tax savings. By partnering with such firms, SMBs can unlock hidden opportunities for growth, innovation, and profitability, ensuring their long-term success in today's competitive landscape.

Strategies for Cost Reduction in Medical Practices: Enhancing Efficiency and Sustainability

Sun, 17 Dec 2023 21:37:40 GMT

As medical practices navigate the complex landscape of healthcare, optimizing financial resources becomes crucial for long-term sustainability.

As medical practices navigate the complex landscape of healthcare, optimizing financial resources becomes crucial for long-term sustainability. In an era where the cost of healthcare is under scrutiny, medical practitioners must proactively seek ways to reduce costs without compromising the quality of patient care. This article explores practical strategies for cost reduction in medical practices, focusing on efficiency improvements and financial sustainability.

Embrace Technology and Electronic Health Records (EHR):
Transitioning to electronic health records (EHR) can significantly streamline administrative processes, reduce paperwork, and minimize the risk of errors. Implementing technology solutions, such as practice management software, can automate routine tasks like appointment scheduling, billing, and inventory management, freeing up staff time for more critical patient care activities.

Negotiate with Suppliers and Vendors:
Regularly review contracts with suppliers, pharmaceutical companies, and equipment vendors to negotiate better rates. Group purchasing organizations (GPOs) can also be explored to leverage collective buying power, obtaining discounts on medical supplies and equipment. Establishing strong vendor relationships can lead to favorable terms and cost-saving opportunities.

Staff Training and Cross-Training:
Invest in ongoing staff training to enhance efficiency and reduce errors. Cross-train employees to perform multiple roles, ensuring that staffing levels remain flexible and responsive to fluctuations in patient volume. This not only improves productivity but also allows the practice to operate more efficiently during peak times without incurring unnecessary labor costs.

Telemedicine and Remote Services:
The adoption of telemedicine can reduce costs associated with physical space, utilities, and support staff. Offering remote consultations and follow-ups can enhance patient accessibility while minimizing overhead expenses. This strategy is especially relevant in the era of digital health, providing a cost-effective alternative to traditional in-person appointments.

Energy Efficiency and Green Practices:
Implement energy-efficient measures within the practice, such as using energy-efficient lighting, appliances, and HVAC systems. Additionally, consider adopting eco-friendly practices like digital documentation to reduce paper usage. Green initiatives not only contribute to environmental sustainability but also result in long-term cost savings.

Billing and Revenue Cycle Management:
Optimize the billing and revenue cycle management processes to minimize revenue leakage and improve cash flow. Regularly review coding practices to ensure accurate billing, and implement effective denial management strategies to reduce the number of rejected claims. Timely billing and follow-up on outstanding payments can enhance financial performance.

Collaborate and Share Resources:
Explore collaborative arrangements with neighboring medical practices or healthcare facilities to share resources and reduce costs. Joint purchasing, shared staffing, and collaborative marketing efforts can create synergies that benefit all parties involved. Building a network of healthcare providers can also facilitate referrals and enhance patient care.

Preventive Maintenance of Equipment:
Regular maintenance of medical equipment helps prevent costly repairs and extends the lifespan of assets. Establish a preventive maintenance schedule for all medical devices, ensuring they are in optimal condition. This approach reduces the risk of unexpected equipment failures and the associated financial burden of emergency repairs or replacements.

Cost reduction in medical practices requires a multifaceted approach that addresses both operational and strategic aspects. By embracing technology, negotiating with vendors, optimizing staffing, and implementing efficient processes, medical practitioners can achieve significant cost savings without compromising the quality of patient care. Continual monitoring of financial performance and a commitment to ongoing improvement will position medical practices for long-term success in a dynamic and challenging healthcare landscape.

Leveraging the Research and Development Tax Credit: A Boon for Hospitals

Sun, 17 Dec 2023 21:27:11 GMT

Research and Development (R&D) activities are integral to the continuous improvement and innovation in the healthcare sector.

Research and Development (R&D) activities are integral to the continuous improvement and innovation in the healthcare sector. Hospitals, in particular, engage in extensive research to enhance patient care, develop cutting-edge medical technologies, and improve overall healthcare outcomes. The Research and Development Tax Credit (R&D Tax Credit) serves as a powerful incentive for hospitals to invest in innovative projects, fostering advancements in medical science while providing financial relief. This article explores the benefits of the R&D Tax Credit for hospitals and how it can be leveraged to support research initiatives.

Understanding the R&D Tax Credit:

The R&D Tax Credit is a government incentive designed to stimulate research and development across various industries, including healthcare. Enacted to encourage innovation, the credit provides a dollar-for-dollar reduction in a company's tax liability for qualified R&D expenditures. While traditionally associated with industries like technology and manufacturing, hospitals are increasingly recognizing the value of this credit in supporting their research initiatives.

Qualifying Activities in Hospitals:

Hospitals engage in a wide range of qualifying R&D activities that may make them eligible for the tax credit. These activities include:

Clinical Trials: Hospitals often conduct clinical trials to test the efficacy and safety of new treatments, drugs, or medical devices. Expenditures related to these trials, such as personnel costs, equipment, and supplies, may qualify for the R&D Tax Credit.

Development of Medical Devices: Designing and developing new medical devices or improving existing ones to enhance patient care and treatment efficiency is a common R&D activity in hospitals.

Drug Development: Research into new pharmaceuticals and therapies to address various medical conditions contributes significantly to the advancement of healthcare. Costs associated with drug development, including research personnel, laboratory supplies, and testing, can be eligible for the tax credit.

Process Improvements: Hospitals continually strive to improve operational efficiency and patient outcomes. Expenditures related to developing and implementing new processes or technologies to achieve these goals may qualify for the R&D Tax Credit.

Benefits for Hospitals:

Financial Incentive: The R&D Tax Credit provides a direct financial incentive for hospitals to invest in research and development. By offsetting a portion of qualifying expenditures, hospitals can redirect funds toward additional R&D initiatives, fostering a culture of innovation.

Competitive Advantage: Hospitals that actively engage in research and development gain a competitive edge by staying at the forefront of medical advancements. This not only enhances the quality of patient care but also attracts top talent and collaborations with industry leaders.

Community Impact: Advancements in healthcare resulting from R&D activities positively impact the local community. By leveraging the tax credit, hospitals can expand their research efforts, addressing community health needs and contributing to the overall well-being of the population.

Long-term Sustainability: Investing in R&D ensures hospitals remain adaptable to evolving healthcare challenges. By leveraging the R&D Tax Credit, hospitals can create a sustainable framework for ongoing innovation, ensuring they can effectively respond to emerging medical trends and patient needs.

The Research and Development Tax Credit offers hospitals a valuable opportunity to support and expand their research initiatives while simultaneously enjoying financial benefits. By taking advantage of this incentive, hospitals can not only enhance the quality of patient care but also contribute to the advancement of medical science, positioning themselves as leaders in the ever-evolving healthcare landscape. It is essential for hospital administrators and finance teams to explore the eligibility criteria and engage with tax professionals to maximize the benefits of the R&D Tax Credit for their institutions and the communities they serve.

Transforming Healthcare: The Crucial Role of Cost Containment and CG Moneta Consulting's Solutions

Tue, 12 Dec 2023 15:33:24 GMT

The healthcare industry is at the intersection of innovation and necessity.

The healthcare industry is at the intersection of innovation and necessity, continuously evolving to meet the demands of a growing and aging population. Amid this dynamic landscape, the importance of cost containment has never been more critical. In this article, we explore the significance of cost containment in healthcare and how CG Moneta Consulting emerges as a strategic partner in reducing costs and upgrading communication infrastructure.

The Imperative of Cost Containment in Healthcare:

Healthcare costs have been on the rise globally, driven by factors such as advancements in medical technology, an aging population, and the increasing prevalence of chronic diseases. Cost containment is imperative to ensure the sustainability and accessibility of healthcare services. Hospitals and healthcare organizations need effective strategies to streamline operations, eliminate inefficiencies, and optimize resource utilization.

Challenges in Healthcare Cost Management:

Controlling costs in healthcare is a multifaceted challenge. Factors such as rising drug prices, complex reimbursement structures, and the need for advanced technologies contribute to financial strain. Additionally, outdated communication infrastructures can hinder operational efficiency and collaboration among healthcare professionals, impacting the quality of patient care.

CG Moneta Consulting: A Strategic Partner in Cost Reduction:

CG Moneta Consulting specializes in providing tailored solutions to address the unique challenges faced by healthcare organizations. Their expertise lies in identifying cost-saving opportunities through comprehensive assessments of operational processes, supply chain management, and technology utilization.

Operational Efficiency through Process Optimization:

CG Moneta Consulting employs a data-driven approach to assess and optimize operational processes within healthcare organizations. By identifying and eliminating redundancies, streamlining workflows, and enhancing resource allocation, the consulting firm helps healthcare providers achieve operational efficiency, ultimately reducing costs without compromising patient care.

Strategic Supply Chain Management:

A significant aspect of cost containment involves strategic supply chain management. CG Moneta Consulting works closely with healthcare organizations to optimize procurement processes, negotiate favorable contracts with suppliers, and implement inventory management systems. This ensures a reliable supply of medical essentials at competitive prices, contributing to overall cost reduction.

Upgrading Communication Infrastructure:

Effective communication is paramount in healthcare for timely and accurate decision-making. CG Moneta Consulting recognizes the importance of upgrading communication infrastructure to enhance collaboration among healthcare professionals. By implementing advanced communication technologies and integrated systems, the consulting firm enables seamless information exchange, improving patient care coordination and reducing the likelihood of errors.

Technology Integration for Cost Savings:

CG Moneta Consulting specializes in the integration of cost-effective technologies to modernize healthcare operations. From electronic health records (EHR) systems to telehealth solutions, the firm assists healthcare providers in adopting and implementing technologies that enhance efficiency, reduce administrative burdens, and ultimately contribute to significant cost savings.

In the ever-evolving landscape of healthcare, cost containment is a pivotal aspect that determines the ability of organizations to deliver quality care sustainably. CG Moneta Consulting emerges as a valuable ally for healthcare providers, offering strategic solutions to reduce costs, optimize processes, and upgrade communication infrastructure. By leveraging their expertise, healthcare organizations can navigate the challenges of cost containment and pave the way for a more efficient and sustainable future in healthcare delivery.

Navigating the Complexity of Prescription Drug Pricing for Hospitals

Tue, 12 Dec 2023 15:14:33 GMT

The healthcare industry faces numerous challenges, and one of the most intricate issues is the pricing of prescription drugs for hospitals.

The healthcare industry faces numerous challenges, and one of the most intricate issues is the pricing of prescription drugs for hospitals. The complexity of this process involves various stakeholders, regulatory frameworks, and market dynamics that collectively contribute to the rising costs of healthcare. In this article, we will delve into the multifaceted nature of pricing prescription drugs for hospitals, exploring the factors that contribute to this complexity and the implications for healthcare providers.

Pharmaceutical Industry Dynamics:

The pharmaceutical industry operates in a highly competitive environment with continuous research and development, leading to innovative and often expensive drugs. Drug manufacturers invest significant resources in bringing new medications to market, and these costs are often reflected in the pricing of the drugs. The challenge for hospitals lies in negotiating fair prices for these medications while ensuring access to cutting-edge treatments for their patients.

Supply Chain Complexity:

The supply chain for pharmaceuticals is intricate, involving manufacturers, wholesalers, and distributors. Each entity along the supply chain adds its markup, contributing to the final cost of drugs. The lack of transparency in this process makes it difficult for hospitals to pinpoint where cost inefficiencies may arise, making negotiations for better pricing a challenging task.

Insurance and Payer Dynamics:

Hospitals often negotiate pricing with insurance companies and payers to determine reimbursement rates for prescription medications. The varying coverage plans and formularies make it challenging for hospitals to predict and manage drug costs effectively. Additionally, the presence of pharmacy benefit managers (PBMs) adds another layer of complexity, as they negotiate on behalf of insurers and can influence drug pricing.

Regulatory Challenges:

Government regulations and policies play a crucial role in shaping drug pricing. Federal programs like Medicaid and Medicare have specific pricing requirements, and changes in legislation can impact the cost structure for hospitals. The ever-evolving regulatory landscape adds uncertainty to the pricing of prescription drugs and requires hospitals to adapt quickly to remain financially viable.

Market Dynamics and Drug Shortages:

The pharmaceutical market is susceptible to fluctuations in drug availability, leading to shortages and increased prices for certain medications. Hospitals must navigate these challenges by finding alternative treatments, managing inventories efficiently, and negotiating with suppliers to mitigate the impact of shortages on patient care.

Research and Development Costs:

Innovation in drug development is essential for advancing healthcare, but it comes at a significant cost. Hospitals must grapple with the ethical dilemma of providing the latest and most effective treatments while managing the financial burden associated with high research and development costs passed on by pharmaceutical companies.

Pricing prescription drugs for hospitals is a multifaceted challenge that requires careful navigation of industry dynamics, supply chain intricacies, payer negotiations, and regulatory frameworks. As healthcare providers strive to deliver high-quality patient care in a financially sustainable manner, addressing the complexity of prescription drug pricing becomes paramount. Collaborative efforts between stakeholders, increased transparency in pricing structures, and innovative policy solutions are essential to ensure that hospitals can continue to provide optimal care without succumbing to the weight of escalating prescription drug costs.

The Financial Strain on Rural Hospitals Post-COVID-19: A Looming Crisis

Mon, 11 Dec 2023 14:11:06 GMT

Rural hospitals have long been the backbone of healthcare in underserved communities.

Rural hospitals have long been the backbone of healthcare in underserved communities, providing essential medical services to residents who may otherwise lack access to care. However, the COVID-19 pandemic has exacerbated the existing financial challenges faced by these institutions, leaving many struggling to maintain their operations. In this article, we will explore the unique financial pressures that rural hospitals are grappling with in the wake of the pandemic.

Declining Patient Revenues

One of the most significant financial blows to rural hospitals during the COVID-19 pandemic has been the decline in patient revenues. Lockdowns, fear of infection, and a shift in healthcare priorities led to a decrease in elective procedures and routine visits. Rural hospitals heavily depend on these sources of income, and the sudden drop in patient volumes has left them with significant revenue shortfalls.

Increased Operational Costs

Simultaneously, rural hospitals have faced escalating operational costs associated with responding to the pandemic. The need for personal protective equipment (PPE), ventilators, and other essential medical supplies strained already tight budgets. Additionally, the cost of hiring and retaining qualified healthcare professionals surged during the pandemic, as the demand for skilled medical staff soared.

Limited Resources and Infrastructure

Rural hospitals often operate with limited resources and outdated infrastructure. The surge in COVID-19 cases exposed the vulnerabilities of these facilities, forcing them to adapt quickly to an unprecedented health crisis. Upgrading facilities to meet pandemic demands strained financial resources even further, leaving many rural hospitals grappling with the need for modernization amid constrained budgets.

Challenges in Telehealth Implementation

The pandemic accelerated the adoption of telehealth services across the healthcare industry. However, rural hospitals faced unique challenges in implementing and sustaining telehealth programs. Limited access to reliable broadband infrastructure in rural areas hindered the widespread adoption of virtual healthcare, leaving these hospitals struggling to provide remote services to their communities.

Critical Access Hospital (CAH) Reimbursement Issues

Many rural hospitals operate as Critical Access Hospitals (CAHs), a designation aimed at ensuring access to healthcare services in underserved areas. However, the reimbursement model for CAHs may not adequately cover the costs associated with providing essential services. Post-COVID-19, the financial viability of these hospitals is at risk due to reimbursement challenges, potentially jeopardizing their ability to continue serving their communities.

Federal and State Funding Uncertainty

While federal and state governments have provided financial assistance to healthcare institutions during the pandemic, the future remains uncertain. Rural hospitals are concerned about the sustainability of such funding and worry that a reduction in financial support could exacerbate their existing challenges.

The financial pressures on rural hospitals post-COVID-19 present a looming crisis that demands urgent attention. Addressing these challenges requires a multifaceted approach, including targeted financial assistance, infrastructure improvements, and policy changes to ensure the long-term viability of rural healthcare institutions. As the healthcare landscape continues to evolve, it is crucial to recognize the essential role that rural hospitals play in the overall well-being of their communities and take proactive measures to support their financial resilience. Failure to do so risks leaving vulnerable populations without access to critical healthcare services when they need them most.

Unveiling the Power of Engineer-Based Cost Segregation in Maximizing Tax Benefits

Sun, 10 Dec 2023 15:12:28 GMT

Cost segregation is a powerful tax strategy that allows real estate owners to accelerate depreciation.

Cost segregation is a powerful tax strategy that allows real estate owners to accelerate depreciation on certain components of their property, resulting in significant tax savings. Engineer-based cost segregation takes this concept a step further, employing the expertise of engineers to meticulously analyze a property's components and classify them for optimal tax advantage. In this article, we will delve into the intricacies of engineer-based cost segregation and explore how this approach unlocks greater tax benefits for property owners.

Understanding Cost Segregation:

Cost segregation is a tax planning strategy that involves reclassifying components of a commercial or residential property for depreciation purposes. Instead of depreciating the entire property over a standard period (typically 27.5 years for residential and 39 years for commercial properties), cost segregation allows property owners to identify and accelerate the depreciation of certain components, such as electrical systems, plumbing, and interior finishes.

The Role of Engineers in Cost Segregation:

Engineer-based cost segregation takes a more granular and detailed approach to the process. Certified professional engineers with expertise in construction and tax regulations conduct a comprehensive study of the property. This involves a thorough examination of blueprints, on-site inspections, and collaboration with construction experts to identify components that qualify for accelerated depreciation. These engineers apply a keen understanding of construction costs, building codes, and tax regulations to maximize the benefits of cost segregation.

Detailed Component Analysis:

Engineer-based cost segregation involves a meticulous examination of a property's components to determine their appropriate classification for tax purposes. Engineers identify items that can be depreciated over shorter recovery periods, such as flooring, lighting, HVAC systems, and specialized equipment. By breaking down the property into these distinct components, property owners can accelerate depreciation and realize immediate tax benefits.

Maximizing Tax Savings:

The primary advantage of engineer-based cost segregation is its potential to unlock higher tax savings compared to traditional methods. By leveraging the expertise of certified engineers, property owners can ensure that every eligible component is identified and properly classified. This results in a more accurate and aggressive depreciation schedule, leading to increased tax deductions in the earlier years of ownership. The immediate tax savings can then be reinvested or used to enhance the property further.

Compliance with IRS Guidelines:

Engineer-based cost segregation adheres to the guidelines set by the Internal Revenue Service (IRS). The detailed studies conducted by engineers provide a robust foundation for tax deductions, and when properly documented, these studies can withstand IRS scrutiny. This compliance ensures that property owners not only benefit from immediate tax savings but also reduce the risk of audits or disputes with tax authorities.

Applicability to Various Property Types:

Engineer-based cost segregation is applicable to a wide range of property types, including office buildings, hotels, warehouses, retail spaces, and manufacturing facilities. Whether the property is newly constructed or acquired through purchase or renovation, engineer-based cost segregation offers flexibility in tailoring the approach to the unique characteristics of each property.

In the realm of tax planning for real estate, engineer-based cost segregation emerges as a sophisticated and effective strategy for maximizing tax benefits. By enlisting the expertise of certified engineers to conduct detailed analyses, property owners can unlock greater depreciation deductions, leading to immediate tax savings. As the real estate landscape continues to evolve, engineer-based cost segregation stands out as a strategic tool for savvy property owners looking to optimize their tax positions and enhance overall financial performance.

Elevating Healthcare Infrastructure: CG Moneta Consulting's Expertise in Crafting and Managing RFPs for Hospital Technology Upgrades

Sun, 10 Dec 2023 13:32:59 GMT

CG Moneta Consulting, a renowned consulting firm, specializes in crafting and managing Request for Proposals (RFPs) tailored to the unique needs of both small and large hospitals.

In the fast-paced world of healthcare, staying abreast of technological advancements is imperative for hospitals to provide optimal patient care, streamline operations, and ensure data security. Small and large hospitals alike face the challenge of navigating the complex landscape of technology upgrades. CG Moneta Consulting, a renowned consulting firm, specializes in crafting and managing Request for Proposals (RFPs) tailored to the unique needs of both small and large hospitals, facilitating seamless technology upgrades that align with their strategic goals.

Understanding Hospital Needs:

CG Moneta Consulting recognizes that each hospital, regardless of size, has distinct requirements and challenges. Their seasoned consultants begin the process by conducting a comprehensive needs assessment. For small hospitals, the focus may be on cost-effective solutions that enhance basic infrastructure, while large hospitals might require scalable, enterprise-level systems. By understanding the specific needs of each client, CG Moneta ensures that the RFP is precisely tailored to address the unique challenges faced by hospitals of varying sizes.

Expertise in Technology Evaluation:

Crafting an RFP for a technology upgrade requires a deep understanding of the available solutions in the market. CG Moneta Consulting boasts a team of experts well-versed in the latest healthcare technologies, including Electronic Health Records (EHR), Telemedicine, Data Analytics, and Cybersecurity. This knowledge enables them to evaluate and include in the RFP the most cutting-edge solutions that will benefit hospitals in optimizing patient care, operational efficiency, and data management.

Customized RFP Documentation:

The success of any technology upgrade initiative lies in the clarity and specificity of the RFP documentation. CG Moneta excels in creating detailed RFPs that outline the hospital's requirements, objectives, and evaluation criteria. For small hospitals, the emphasis may be on modular solutions that can be implemented incrementally, while large hospitals may require integrated systems for comprehensive healthcare management. By customizing the RFP documentation, CG Moneta ensures that potential vendors understand the unique nuances of each hospital's technology needs.

Vendor Selection and Management:

Once the RFP is disseminated, CG Moneta Consulting takes charge of the vendor selection process. Their experience allows them to efficiently sift through proposals, assess vendor capabilities, and ensure alignment with the hospital's goals. For small hospitals with limited resources, CG Moneta identifies vendors offering cost-effective yet robust solutions. In the case of larger hospitals, the focus is on scalability, interoperability, and integration with existing systems. Throughout the selection process, CG Moneta acts as a liaison between the hospital and potential vendors, facilitating communication and negotiations.

Project Implementation Oversight:

The role of CG Moneta Consulting extends beyond the RFP process. They actively oversee the implementation of the chosen technology upgrade, ensuring that it aligns with the proposed timeline, budget, and performance expectations. For small hospitals, this may involve phased implementation to minimize disruption, while large hospitals may require more intricate project management to coordinate multiple components and stakeholders. CG Moneta's hands-on approach ensures a smooth transition from planning to execution.

In the dynamic landscape of healthcare technology, CG Moneta Consulting stands out as a trusted partner for hospitals seeking to upgrade their systems. Whether working with small community hospitals or large medical centers, CG Moneta's expertise in crafting and managing RFPs ensures that the technology upgrade process is tailored to meet the unique needs and challenges faced by healthcare institutions of all sizes. By choosing CG Moneta Consulting, hospitals can confidently embrace technological advancements, secure in the knowledge that their upgrade initiatives are in the hands of seasoned professionals dedicated to their success.

Revolutionizing the Road: The Crucial Role of Modern Technology in Automobile Dealerships

vgargione@cgmoneta.com (Vincent Gargione) — Sun, 10 Dec 2023 13:12:17 GMT

The automotive industry is not immune to the transformative power of modern technology.

In an era characterized by rapid technological advancements, the automotive industry is not immune to the transformative power of modern technology. Automobile dealerships, once primarily reliant on traditional sales and marketing strategies, are now recognizing the importance of integrating cutting-edge technology into their operations. From customer engagement to inventory management, the adoption of modern technology has become a key driver in enhancing efficiency, customer satisfaction, and overall success in the highly competitive automotive market.

Enhanced Customer Experience:

Modern technology has redefined the way customers interact with automobile dealerships. Virtual showrooms, augmented reality (AR), and virtual reality (VR) experiences allow potential buyers to explore and customize vehicles from the comfort of their homes. This not only saves time but also provides a more immersive and personalized buying experience. Additionally, chatbots and artificial intelligence (AI) tools are increasingly being used to respond to customer inquiries promptly, enhancing communication and improving overall customer satisfaction.

Digital Marketing and Online Presence:

The digital landscape has become a critical battleground for businesses, including automobile dealerships. Establishing a robust online presence through websites, social media, and digital advertising is essential for reaching and engaging with a wider audience. Advanced analytics and customer relationship management (CRM) tools help dealerships understand consumer behavior, enabling them to tailor marketing strategies for maximum impact. Leveraging search engine optimization (SEO) techniques ensures that potential buyers can easily find the dealership online, boosting visibility and sales opportunities.

Inventory Management and Automation:

Gone are the days of manually tracking inventory and managing paperwork. Modern technology has introduced sophisticated inventory management systems that automate various processes, such as tracking vehicle availability, updating pricing, and managing paperwork digitally. This not only streamlines operations but also minimizes the risk of errors and reduces administrative overhead. Dealerships can efficiently manage their inventory, ensuring that the right vehicles are in stock to meet customer demand.

Online Sales Platforms:

The rise of online sales platforms has revolutionized the way cars are bought and sold. Dealerships that embrace e-commerce platforms and digital sales tools can tap into a broader market, reaching customers beyond their geographical location. Online transactions, digital paperwork, and secure payment gateways facilitate a seamless buying process. Moreover, these platforms often provide real-time inventory updates, pricing information, and financing options, making the purchasing journey more transparent and convenient for customers.

Data-Driven Decision-Making:

Modern technology empowers automobile dealerships with the ability to collect and analyze vast amounts of data. Utilizing data analytics tools, dealerships can gain insights into customer preferences, market trends, and operational efficiency. This information is invaluable for making informed decisions, optimizing marketing strategies, and tailoring inventory to meet changing consumer demands. Data-driven decision-making enables dealerships to stay agile in a dynamic market and remain ahead of the competition.

In conclusion, the integration of modern technology is not merely a luxury but a necessity for automobile dealerships aiming to thrive in today's competitive landscape. From enhancing the customer experience to streamlining operations, the benefits of embracing technology are manifold. Dealerships that leverage the power of modern technology are better positioned to adapt to changing consumer expectations, improve efficiency, and build lasting relationships with their customers. As the automotive industry continues to evolve, the role of technology in shaping the future of automobile dealerships cannot be overstated.

The Devastating Ripple Effects: Hyperinflation's Impact on the Healthcare Industry

Sat, 09 Dec 2023 12:49:43 GMT

Hyperinflation, a phenomenon characterized by an uncontrollable increase in the prices of goods and services, has far-reaching consequences.

Hyperinflation, a phenomenon characterized by an uncontrollable increase in the prices of goods and services, has far-reaching consequences that extend beyond the realms of economics. One sector profoundly affected by hyperinflation is the healthcare industry. As prices skyrocket and currency values plummet, healthcare providers face unprecedented challenges, jeopardizing the delivery of essential services and the overall well-being of populations.

Escalating Costs of Medical Supplies and Equipment:

Hyperinflation leads to a surge in the costs of medical supplies and equipment. Pharmaceutical companies, medical device manufacturers, and other suppliers face higher production costs, which are often passed on to healthcare providers. As a result, hospitals and clinics grapple with inflated expenses for essential items like medications, surgical instruments, and diagnostic equipment. The strain on budgets can compromise the quality of care and limit the availability of crucial resources.

Erosion of Healthcare Worker Salaries:

In hyperinflationary environments, the real value of wages diminishes rapidly. Healthcare professionals, including doctors, nurses, and support staff, find their salaries insufficient to cover basic living expenses. This financial strain can lead to demotivation, burnout, and even migration of skilled healthcare workers seeking better opportunities abroad. The exodus of qualified personnel exacerbates the challenges faced by healthcare systems, resulting in a shortage of trained professionals.

Accessibility and Affordability Issues for Patients:

As the costs associated with healthcare provision soar, patients bear the brunt of hyperinflation. Affordability becomes a significant concern, leading to delayed or foregone medical treatment. Essential medications, routine check-ups, and preventive care measures may become financially out of reach for a significant portion of the population. The consequences can be severe, with individuals foregoing necessary medical attention until conditions worsen, leading to increased morbidity and mortality rates.

Strain on Healthcare Infrastructure:

Hyperinflation strains healthcare infrastructure in multiple ways. In addition to the increased costs of medical supplies and personnel, maintaining and upgrading facilities becomes a formidable challenge. Infrastructure development projects may stall, and the ability to invest in new technologies and medical advancements may be severely restricted. This stagnation hampers the healthcare industry's capacity to adapt to evolving medical needs and limits the quality of care provided.

Impact on Public Health Programs:

Public health initiatives, crucial for disease prevention and control, are also adversely affected by hyperinflation. Budget constraints limit the resources available for vaccination campaigns, health education programs, and disease surveillance. This, in turn, increases the vulnerability of communities to infectious diseases, potentially leading to public health crises that could have been prevented with adequate funding and resources.

Conclusion:

Hyperinflation's impact on the healthcare industry is multifaceted, affecting every aspect of the provision and accessibility of healthcare services. As economies grapple with the challenges of hyperinflation, governments and policymakers must prioritize strategies to safeguard the healthcare sector. This includes implementing measures to stabilize currencies, securing affordable access to medical supplies, and addressing the financial well-being of healthcare workers. Failure to address these issues can lead to long-lasting consequences, with potentially devastating effects on the health and well-being of entire populations.

Navigating Healthcare Economics: Cost Reduction Strategies for Hospitals

Sat, 09 Dec 2023 11:43:50 GMT

In the complex landscape of healthcare, hospitals face a perpetual challenge to balance providing quality patient care with managing costs effectively.

In the complex landscape of healthcare, hospitals face a perpetual challenge to balance providing quality patient care with managing costs effectively. With the ever-increasing demands on healthcare resources and a need for financial sustainability, hospitals must adopt strategic approaches to reduce costs without compromising patient outcomes. In this blog post, we will explore some proven cost reduction strategies for hospitals.

Supply Chain Optimization:

Hospitals can achieve significant cost savings by optimizing their supply chain processes. Negotiating bulk purchasing agreements, implementing just-in-time inventory management, and leveraging technology for supply chain visibility are effective ways to reduce costs without compromising the quality of care.

Energy Efficiency Initiatives:

Energy consumption constitutes a substantial portion of a hospital's operational costs. Implementing energy-efficient technologies, such as LED lighting, smart HVAC systems, and energy-efficient appliances, can lead to long-term savings. Additionally, hospitals can explore renewable energy sources like solar power to further reduce energy expenses.

Telemedicine Integration:

The rise of telemedicine provides hospitals with an opportunity to enhance patient care while reducing costs associated with in-person visits. By incorporating telehealth services, hospitals can streamline operations, reduce the need for physical infrastructure, and enhance the overall efficiency of healthcare delivery.

Staff Training and Retention:

High turnover rates among healthcare professionals can contribute to increased recruitment and training costs. Hospitals can invest in ongoing training programs to enhance staff skills, job satisfaction, and retention. A satisfied and well-trained workforce not only improves patient care but also reduces the need for frequent recruitment and training.

Data Analytics for Operational Efficiency:

Leveraging data analytics tools can help hospitals identify inefficiencies in their operations. By analyzing patient flow, resource utilization, and other key performance indicators, hospitals can make informed decisions to optimize processes, allocate resources more efficiently, and ultimately reduce operational costs.

Preventive Care and Population Health Management:

Shifting the focus from reactive to preventive care can yield long-term cost savings. Hospitals can invest in programs that promote health and wellness, manage chronic conditions, and prevent avoidable hospital admissions. Proactive population health management can result in healthier communities and reduced healthcare expenditures over time.

Outsourcing Non-Core Functions:

Hospitals can achieve cost savings by outsourcing non-core functions, such as billing, coding, and IT services. This allows the hospital staff to concentrate on core clinical functions while benefiting from the specialized expertise of external service providers.

Collaboration and Partnerships:

Collaborating with other healthcare organizations, forming strategic partnerships, and sharing resources can lead to economies of scale. Shared services, joint purchasing initiatives, and collaborative clinical programs can contribute to cost reduction while maintaining or even improving the quality of care.

In the face of economic challenges, hospitals must proactively seek and implement cost reduction strategies to ensure financial stability without compromising the quality of patient care. By embracing technology, fostering collaboration, and optimizing operational processes, hospitals can navigate the complex healthcare landscape while delivering value to their communities. The pursuit of cost reduction is not just an economic imperative but a commitment to building a sustainable and resilient healthcare system for the future.

Navigating the Fiscal Landscape: Specialized Tax Incentives for Hospitals

vgargione@cgmoneta.com (Vincent Gargione) — Wed, 06 Dec 2023 18:19:04 GMT

Hospitals play a crucial role in providing essential healthcare services to communities.

Hospitals play a crucial role in providing essential healthcare services to communities, and recognizing their societal impact, governments often extend specialized tax incentives to support their financial sustainability and growth. These incentives are designed to encourage hospitals to invest in specific areas, improve patient care, and contribute to the overall well-being of the community. In this article, we explore some of the specialized tax incentives available for hospitals, highlighting their significance in the complex world of healthcare finance.

Charitable Contribution Deductions:

Hospitals that operate as nonprofit entities may qualify for charitable contribution deductions. Donors contributing to these hospitals can often deduct their contributions from their taxable income. This encourages philanthropy, enabling hospitals to secure additional funding for research, community outreach programs, and the provision of healthcare services to underserved populations.

Tax-Exempt Status:

Nonprofit hospitals are generally eligible for tax-exempt status under section 501(c)(3) of the Internal Revenue Code. This status exempts qualifying hospitals from federal income tax, allowing them to allocate more resources to patient care, research, and community health initiatives. However, to maintain this status, hospitals must meet specific criteria, such as providing a certain level of charity care and conducting community benefit programs.

Depreciation Deductions:

Hospitals often invest heavily in medical equipment and facilities. The tax code allows them to claim depreciation deductions on these assets, spreading the cost over time. This not only reduces the immediate financial burden on hospitals but also encourages them to continuously update their equipment and infrastructure to provide cutting-edge medical services.

Work Opportunity Tax Credit (WOTC):

The WOTC is a federal tax credit aimed at encouraging employers, including hospitals, to hire individuals from specific target groups facing challenges in the labor market. This includes veterans, individuals with disabilities, and certain recipients of government assistance. By participating in the WOTC program, hospitals can reduce their federal tax liability while contributing to the employment and economic well-being of these groups.

Research and Development (R&D) Tax Credits:

Hospitals engaged in medical research may qualify for R&D tax credits. These credits are designed to incentivize organizations to invest in innovative and technologically advanced research initiatives. Hospitals conducting research to develop new treatments, drugs, or medical technologies can benefit from these credits, reducing their tax liability and fostering advancements in healthcare.

State-Level Incentives:

In addition to federal incentives, hospitals may also be eligible for various state-level tax incentives. States often offer credits or exemptions to encourage specific activities, such as the construction of new healthcare facilities, hiring healthcare professionals, or investing in telemedicine infrastructure.

Conclusion:

Specialized tax incentives serve as powerful tools to support hospitals in fulfilling their vital role in society. By leveraging these incentives, hospitals can enhance their financial viability, invest in cutting-edge technologies, and expand their capacity to provide quality healthcare services. As the healthcare landscape continues to evolve, understanding and maximizing the benefits of these tax incentives can contribute to the overall well-being of both hospitals and the communities they serve.

Demystifying Healthcare Billing: Understanding the Difference Between 837 and 835

Wed, 06 Dec 2023 17:54:20 GMT

In the complex landscape of healthcare billing, efficient and accurate communication between healthcare providers and payers is crucial.

In the complex landscape of healthcare billing, efficient and accurate communication between healthcare providers and payers is crucial for smooth financial transactions. Two essential electronic transaction standards that play a pivotal role in this process are the 837 and 835. These standards, developed by the Accredited Standards Committee (ASC) X12, govern the exchange of healthcare claim and payment information. In this article, we will delve into the key distinctions between the 837 and 835 transactions in the realm of healthcare billing.

837 Transaction: The Claim Submission

The 837 transaction, also known as the Health Care Claim: Professional (837P) or Institutional (837I), is used by healthcare providers to submit claims to payers. This electronic format streamlines the submission process, reducing errors and accelerating the reimbursement cycle. The 837 includes comprehensive information about the services rendered, such as:

Patient information
Provider details
Procedure and diagnosis codes
Service dates
Claim amounts and charges

Essentially, the 837 serves as the bridge between healthcare providers and payers, ensuring that accurate and detailed information is communicated for reimbursement.

835 Transaction: The Electronic Remittance Advice (ERA)

Contrary to the 837, the 835 transaction deals with the payment side of healthcare billing. It is known as the Health Care Claim Payment/Advice (835) and serves as the Electronic Remittance Advice (ERA). The 835 provides a detailed explanation of payments made by the payer to the healthcare provider. Key components of the 835 include:

Payment information (amount paid, adjustments, etc.)
Claim details (reference numbers, dates)
Adjustment reason codes
Patient responsibility information
Provider information

By leveraging the 835 transaction, healthcare providers can reconcile their accounts receivable, track payment discrepancies, and identify any denied or adjusted claims.

Interconnected Workflow: The Claim Lifecycle

Understanding the relationship between the 837 and 835 is crucial for comprehending the end-to-end healthcare billing process. The workflow typically unfolds as follows:

837 Submission : Healthcare providers transmit claims electronically to payers using the 837 format, initiating the billing process.
Payer Processing : Payers receive the 837 claims and process them, determining the appropriate reimbursement amounts and any adjustments.
835 Remittance : Payers send the 835 transaction to healthcare providers, detailing the payment information and reasons for any adjustments made during processing.
Reconciliation : Healthcare providers use the information in the 835 to reconcile their accounts, ensuring that payments align with the submitted claims.

Benefits of Standardization: Enhanced Efficiency and Accuracy

The utilization of standardized formats like the 837 and 835 brings several benefits to the healthcare billing process. Standardization streamlines communication, reduces manual errors, and accelerates reimbursement cycles. Additionally, it facilitates interoperability among different healthcare systems and ensures compliance with regulatory requirements.

Conclusion:

In the intricate landscape of healthcare billing, the 837 and 835 transactions play indispensable roles in facilitating the exchange of claim and payment information between healthcare providers and payers. By understanding the nuances of these electronic standards, stakeholders can optimize their billing processes, enhance efficiency, and ensure accurate financial transactions in the dynamic healthcare ecosystem.

The Hidden Battle: Insurance Payers Underpaying Hospitals and Healthcare Organizations

Tue, 05 Dec 2023 12:17:53 GMT

Unraveling the Financial Struggle: The Silent Battle Impacting Hospitals and Healthcare Access

In the intricate web of the healthcare system, a silent battle is raging between insurance company payers and hospitals or healthcare organizations. While insurance is meant to provide a safety net for individuals seeking medical care, the underpayment issue has become a significant challenge for healthcare providers. In this blog, we will delve into the complexities of this problem, exploring the reasons behind underpayment, its impact on hospitals, and potential solutions.

The Underpayment Conundrum:

Healthcare providers, including hospitals and medical facilities, play a critical role in maintaining public health. However, an alarming trend has emerged where insurance company payers are underpaying these essential institutions. This underpayment occurs when the reimbursement rates negotiated between insurance companies and healthcare providers fall short of covering the actual cost of services.

Reasons Behind Underpayment:

Negotiation Power Imbalance:
Insurance companies, being large entities with substantial negotiating power, often dictate terms that favor their financial interests. This power imbalance puts healthcare providers at a disadvantage during contract negotiations.
Complex Reimbursement Models:
The complexity of reimbursement models contributes to the underpayment issue. Some insurance companies use convoluted systems that make it challenging for healthcare providers to accurately estimate reimbursement amounts, leading to unexpected shortfalls.
Low Medicaid and Medicare Reimbursement Rates:
Hospitals heavily rely on Medicaid and Medicare reimbursements, but these government-sponsored programs often have lower reimbursement rates compared to private insurers. This discrepancy places an additional financial burden on healthcare providers.

Impact on Hospitals and Healthcare Organizations:

Financial Strain:
Underpayment exacerbates the financial strain already faced by hospitals, making it difficult for them to invest in modern equipment, attract skilled staff, and maintain the quality of care provided.
Threat to Patient Care:
With limited resources, healthcare organizations may be forced to cut corners, compromising patient care. This can lead to a decline in the quality of services and, in extreme cases, closures of healthcare facilities in financially precarious situations.
Reduced Access to Services:
Underpayment can also result in reduced access to healthcare services, particularly in underserved communities. Hospitals may limit the range of services offered or close altogether, leaving communities without vital healthcare resources.

Solutions and the Way Forward:

Advocacy for Fair Reimbursement:
Healthcare providers must engage in advocacy efforts to ensure fair reimbursement rates. This may involve collaboration with policymakers to address the root causes of underpayment and promote transparency in reimbursement negotiations.
Streamlining Reimbursement Processes:
Simplifying and standardizing reimbursement processes can help minimize confusion and ensure that healthcare providers receive fair compensation for their services.
Policy Reforms:
Policymakers should explore reforms that address the power imbalance between insurance companies and healthcare providers. This might involve implementing regulations that promote fair negotiations and prevent predatory practices.

The underpayment issue between insurance company payers and healthcare providers is a critical challenge that requires urgent attention. As stakeholders in the healthcare system, we must work towards a more equitable and transparent reimbursement framework that ensures the sustainability of healthcare organizations and, ultimately, the well-being of patients. By addressing the root causes and advocating for positive change, we can foster a healthcare system that serves the needs of all its participants.

Specialized Tax Incentives for the Medical & Health Care Industry

dcovell@cgmoneta.com (Daniel Covell) — Tue, 03 Aug 2021 13:12:26 GMT

How much money is available?

If you have yet to hear; Local, State, and Federal Governments have been feverishly enacting numerous incentives to help stimulate business economies. Due to the high tax brackets of most medical practitioners, these incentives are now an essential part of the tax planning process. If you haven’t had a thorough review of your qualifications for incentives, keep reading.

How Much Money is Available?

The average available benefit for a small practice with their own building is $160,000.

Who Qualifies?

The following is a list of common qualified practitioners:

Physicians
Dentists & Orthodontists
Dermatology & Skin Care
Vision & Eye Care
General Practicioners
Surgeons
Therapists
Medical Imaging

How Do I Qualify?

You may qualify if you meet any of the following:

Own Commercial Property
Directly Employ U.S. Staff
Pay Real or Personal Property Tax
Pay State or Federal Income Tax
Perform Energy Efficiency Upgrades
Upgraded Equipment Purchases

How Do I Learn More?

If you would like a thorough analysis of incentive dollars available for you, please contact us today.

"Research & Development, I don't think we do that!"

dcovell@cgmoneta.com (Daniel Covell) — Tue, 03 Aug 2021 13:04:00 GMT

The IRS changed the definition of R&D

If, when you hear R&D, you think of people in lab coats tinkering with chemicals, ultra high tech industries and Fortune 500 companies, you are not alone. However, things have changed!

In 2001 the IRS changed the definition of R&D and the changes were so broad that it virtually encompasses all manufacturing or technology organization in some way.

Why is this? It’s because, by and large what do manufacturing companies do? They design new products, improve existing products, come up with new processes, or make improvements to existing processes used to make products. Most of these organizations don’t have an R&D department and probably don’t consider that what they are doing is “R&D”. They are making these improvements and changes because they MUST stay competitive and yet, as the government sees it, “R&D” is exactly what they are doing.

Here are some of the everyday activities that would qualify for the credit:

Designing the process to fabricate the metal to reduce shrinkage and increase its quality
Programming CNC machines
3D CAD Engineering with programs like SolidWorks
Developing and testing of prototypes
Quality assurance – First-piece quality inspections
Designing and developing of specialty tooling and fixtures
Considering alternative metals to develop the product
Considering different metal thicknesses
Developing engineering drawings
Developing weld procedures
Bending of metal (e.g. sheet metal) has to consider the stressing and stretching
Considering strength of final product for application (meets specifications)

So, the next obvious question is…”How do We get some money?” The IRS allows companies to go back three open tax years to take advantage of the credits they may have missed. (Nice of them isn’t it?) Just 120 days after submitting the amended returns, you can get cash in your pocket. Additionally, you can take credits for current and future years if you continue to perform activities that qualify for this credit.

To find out if your organization would qualify ask yourself a few questions:

Are you expecting to be profitable this year, or were you profitable in any of the last 4 years?
Is your average annual payroll for these years in excess of $1 million?
Is your company structure a C Corp, or an S Corp/Partnership?

If you answered yes to all of these items then you definitely need to have an R&D Tax Consulting firm take a look at your organization. You could potentially have a five-figure credit, even higher credits are available for organizations with higher payrolls.

For Most Companies, Finding New Profit Centers is a Must

Tue, 03 Aug 2021 12:53:23 GMT

Cashflow is King.

“Profit Center”, it’s the new buzzword being tossed around like a football across corporate America. It sure sounds good, doesn’t it? Of course it does, who doesn’t like profits? Unfortunately saying the words “Profit Center” and actually having one are two different ball games.

To put it simply, a Profit Center is defined as, “The branch or division of a company that creates profits individually and separately from the main organization.”

There are essentially two methods of creating a profit center for your organization. First, you can offer a new service that creates a profitable revenue stream. Second, a cost center can turn into a profit center by selling those administrative “cost of doing business” services to other firms. As Management Professor William E. Halal so eloquently stated to USA Today Magazine, “When a business firm becomes a corporate community of entrepreneurs who buy, sell and launch new products and services internally as well as externally, it gains the same creative interplay that makes market economies so advantageous.”

For the purpose of this article we will focus on creating a new profit center rather than converting a cost center into a profit center. The easiest way to create a new profit center is to add service offerings that align with an existing client base.

For example, CPAs, A/E/C firms, Commercial Real Estate Professionals, and even most Contractors have an existing base of business clients and referral partners who own commercial property. Are they maximizing on the plethora of accumulated property data, let alone the hard-earned relationships they've developed? These are not cold leads or warm contacts but EXISTING CLIENTS who have already paid money for their services. Failing to monetize an existing client base with value-added services is just bad business.

So, how do I create a new service offering and market it to my existing client base? The easiest way to accomplish this is to partner with an organization that already has a profitable service on the market that would be a benefit to your clients. Once a partnership is established, the next step is to effectively spread the word to your existing client base. Communicate how your new opportunities will benefit them and move them through the sales cycle. If you have done it right, your existing clients will thank you for your high level of client service. This truly becomes a “win-win-win” proposition!

CG Moneta LLC provides custom services to business owners across the nation to increase sales, reduce cost, and procure specialized tax incentives. CG Moneta also offers strategic partnership to firms looking to utilize their existing client relationships to generate new revenue streams.